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Nederlandse samenvatting
–Summary in Dutch–
Fractionele calculus kan beschouwd worden als een veralgemening van klassieke
afgeleiden en integralen, waarbij de orde nu ook niet-geheel kan zijn. Principes
en methodes uit de fractionele calculus zijn ook van nut voor systemen die kunnen
worden gemodelleerd door fractionele differentiaalvergelijkingen (die dus afgelei-
den van niet-gehele orde bevatten). Dit worden fractionele-orde (FO) systemen
genoemd en ze zijn nuttig om een atypisch gedrag (bijvoorbeeld diffusie) van
dynamische systemen te karakteriseren. Voor een gehele-orde systeem varieert de
magnitude in de Bode karakteristiek met een geheel veelvoud van 20 dB/decade
(±20 dB/dec, ±40 dB/dec, ...) en de fase met een geheel veelvoud van 90◦ (±
90◦, ±180 ◦, ...). Voor een FO systeem met een fractionele orde n varieert de
magnitude met n · 20 dB/dec en evenzo zal de fase varieren met n · 90◦.
Dynamische systemen die op een natuurlijke wijze aan de hand van fractionele
orde modellen kunnen beschreven worden vertonen specifieke kenmerken, zoals
visco-elasticiteit, diffusie en een fractale structuur. Het ademhalingssysteem is hi-
ervan een ideaal voorbeeld. Hoewel de visco-elastische en diffuse eigenschappen
van het ademhalingssysteem reeds intensief werden onderzocht, werd de fractale
structuur tot nog toe genegeerd. Een van de redenen is wellicht dat de luchtwegen
geen perfecte symmetrie vertonen, dus niet echt voldoen aan een van de voor-
waarden om een typisch fractale structuur te zijn. Toch kan men een zekere mate
van recurrentie herkennen in de modellen die worden gebruikt voor het beschri-
jven van de luchtwegenstructuur. In dit proefschrift zal de fractionele calculus
toegepast worden om de gasdiffusie in de menselijke longen te modelleren en om
de geneesmiddelendiffusie in het menselijk lichaam te karakteriseren.
Het ademhalingsstelsel bezit de drie hierboven opgesomde eigenschappen en
er is geen enkele reden waarom men een van deze zou moeten negeren. Bovendien
wordt in het geval van aandoeningen de visco-elasticiteit beinvloed door veran-
deringen op cellulair niveau die ook de oorzaak zijn van lokale vernauwingen en
afsluitingen, die dan op hun beurt een invloed hebben op zowel de structuur van
het luchtwegenstelsel als op de diffusieoppervlakte. Als een specifiek model (bv.
een elektrisch analogon) van de luchtwegen zou bestaan, dan zou dit kunnen ge-
bruikt worden voor simulatiedoeleinden, zowel bij gezonde als bij pathologische
gevallen.
In de alveoli van zoogdierlongen diffundeert zuurstof door verschillen in par-
tile druk over het alveolaire capillaire membraan. De longen hebben een grote
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diffusieoppervlakte om dit gasuitwisselingsproces te vergemakkelijken. Eigenlijk
kan de verspreiding van om ’t even welke grootheid die kan worden beschreven
door de diffusievergelijking of door een random walk model (bijvoorbeeld con-
centratie, warmte, enz.) diffusie worden genoemd. Verschillende factoren zoals
pathologien, lichaamsbeweging en een ongebruikelijke omgeving, kunnen de gasuit-
wisseling in de longen beperken (d.w.z. de zuurstof beperken die de longen bin-
nendringt). Bij sommige ziekten, zoals emfyseem en interstitile longziekte, wordt
het capillaire bed verminderd, wat resulteert in een verminderde tijd beschikbaar
voor bloedoxygenatie. Bij longoedeem en interstitile fibrose kan daarentegen de
bloed-gas barrire abnormaal worden verdikt wat dan de diffusiecapaciteit vermin-
dert. In dit proefschrift wordt de relatie bestudeerd tussen wiskundige modellen
voor diffusie enerzijds en niet-invasieve metingen van de longfunctie anderzijds.
De tweede toepassing van diffusie die in dit proefschrift wordt behandeld is
de verspreiding van medicijnen in het menselijk lichaam. Ten behoeve van het
regelen van anesthesie kan wiskundige modellering van medicijndiffusie erg nut-
tig zijn om het mechanisme van medicijnafgiftesystemen beter te begrijpen. De
beschrijving van medicijntransport in het menselijk lichaam stelt ons in staat om
enerzijds het mechanisme te begrijpen en om anderzijds een kwantitatieve voor-
spelling te doen van de effecten van formulering en verwerkingsparameters op de
resulterende medicijnafgiftekinetiek. De grootste uitdaging bij de ontwikkeling en
optimalisatie van geautomatiseerde systemen voor toediening van geneesmidde-
len is het bereiken van een optimale geneesmiddelenconcentratie op de plaats van
actie. Om het optimale concentratie-tijd profiel op de plaats van actie te hebben,
moet de afgifte van het geneesmiddel zo nauwkeurig mogelijk worden geregeld.
Drie componenten bepalen de algemene anesthesietoestand van de patint: hyp-
nose (gebrek aan bewustzijn, gebrek aan geheugen), analgesie (gebrek aan pijn) en
neuromusculaire blokkade (gebrek aan beweging). In de literatuur zijn verschil-
lende schema’s voor het induceren en handhaven van hypnose en neuromusculaire
blokkade voorgesteld. Deze twee deelcomponenten van anesthesie zijn momenteel
tot voldoende rijpheid gekomen om hen te integreren in n enkel platform voor klin-
ische anesthesie. Hypnotische en opiode (pijnstillende medicatie) bijwerkingen
resulteren in veranderingen in andere biosignalen zoals hartslag, ademhalingssnel-
heid, gemiddelde arterile druk, gas in- en uitademingspercentages, lichaamstem-
peratuur, enz. Binnen het anesthesie-paradigma is de detectie en het kwantificeren
van pijn - via een objectieve meting die wordt ondersteund door een wiskundig
model - nog steeds een ontbrekend stuk in de puzzel (ondanks enkele monitoren
die recent op de markt beschikbaar gekomen zijn, bv. Medstorm, Medasense, Al-
giscan). Op zich is pijn een zeer complex proces, waarbij een groot aantal chemis-
che, fysische en elektrische subprocessen betrokken zijn, allemaal gebundeld in n
grootschalig systeem.
In dit proefschrift zijn de eerste stappen gezet in de richting van enerzijds een
sensor om het pijnniveau op een objectieve manier te meten en anderzijds een
model om mathematisch de signaalroutes van nociceptor-excitatie te modelleren.
Het resultaat is de ANSPEC-PRO monitor, die op een niet-invasieve manier de
pijn meet door middel van huidimpedantie. Het prototype is op dit moment alleen
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gevalideerd bij wakkere vrijwilligers met zelf-geinduceerde nociceptor-excitatie
(d.w.z. mechanische pijnstimuli). Deze eerste resultaten moeten het pad effenen
naar een compleet regelplatform voor algemene anesthesie door middel van zijn
drie componenten: hypnose, analgesie en neuromusculaire blokkade.
Dit proefschrift is als volgt gestructureerd:
In Hoofdstuk 1 wordt een korte geschiedenis van fractionele calculus beschreven
evenals het gebruik ervan in de biomedische ingenieurstechnieken.
Hoofdstuk 2 behandelt de diffusietheorie in poreuze media. De inleidende con-
cepten over diffusie voorgesteld in dit hoofdstuk worden verder in het proefschrift
toegepast bij het modelleren van diffusie in de longen en bij geneesmiddelendif-
fusie in het menselijk lichaam.
In Hoofdstuk 3 wordt gedetailleerd beschreven hoe de principes en methodes
uit de fractionele calculus gebruikt kunnen worden voor de modellering van het
ademhalings-systeem. De diffusieconcepten worden besproken vanuit het per-
spectief van gasuitwisseling in de longen en met betrekking tot de wijze waarop
de diffusiefactor de voortgang van ziektes benvloedt.
In Hoofdstuk 4 wordt een geleidelijke overgang van het modelleren van dif-
fusie in de longen naar het modelleren van geneesmiddelendiffusie voorgesteld.
Een gedetailleerde beschrijving van de bestaande methodes en tools voor pijnbeo-
ordeling samen met hun voor- en nadelen wordt voorgesteld. Dit hoofdstuk leidt
tot het besluit dat er geen mathematisch-fysiologisch gebaseerd model beschikbaar
is voor de beschrijving van de nociceptieve route. Deze uitdaging wordt verder be-
handeld in hoofdstukken 5 en 6.
Hoofdstuk 5 introduceert het gebruik van diffusieprocessen voor de karakter-
isatie van de werking van een geneesmiddel. Om de evolutie van de geneesmidde-
len in het menselijk lichaam te beschrijven worden er compartimentele farmaco-
kinetische en farmaco-dynamische modellen gebruikt. In dit hoofdstuk wordt een
analyse van atypische diffusie gellustreerd en wordt het farmaco-kinetisch model
herzien.
In Hoofdstuk 6 worden de eerste stappen gezet in de richting van een mathema-
tisch model voor nociceptie en een geconcentreerd fractionele orde model wordt
afgeleid. Dit model werd gevalideerd met metingen uitgevoerd met de recentste
technologie voor pijnbeoordeling. De resultaten bekomen voor de pijnevaluatie bij
een groep van vrijwilligers worden weergegeven.
De besluiten van dit doctoraatsproefschrift worden voorgesteld in Hoofdstuk
7.

English summary
Fractional calculus is a generalization of classical integer-order integration and
differentiation (non-integer) order operators. Tools from fractional calculus can
be also used for general systems that can be modeled by fractional differential
equations containing derivatives of non-integer order. These are called fractional
order systems they are useful to characterize anomalous behavior (e.g. diffusion)
of dynamical systems. In the case of an integer order system, the magnitude varies
with an integer multiple of 20 dB/dec (±20dB/dec, ±40dB/dec, etc) and the
phase with an integer multiple of 90◦ (± 90◦, ± 180◦ ). In the case of fractional
order systems, the magnitude varies with n · 20dB/dec and the phase will vary
with n · 90 ◦ (n is the fractional order operator).
Dynamical systems whose model can be approximated in a natural way using
FO terms, exhibit specific features, such as viscoelasticity, diffusion and a frac-
tal structure; hence the respiratory system is an ideal application for FO models.
Although viscoelastic and diffusive properties were intensively investigated in the
respiratory system, the fractal structure was ignored. Probably one of the reasons
is that the respiratory system does not pose a perfect symmetry, hence failing to
satisfy one of the conditions for being a typical fractal structure. Nonetheless,
some degree of recurrence has been recognized in the airway generation models.
The respiratory system poses all three properties enumerated above and there
is no reason why one should ignore either one of them. Moreover, with pathology,
viscoelasticity is affected by changes at the cellular level, narrowing or occluding
the airway, which in turn affects both the structure of the airway distribution, as
well as the diffusion area. If a specific model (e.g. an electrical analogue) of the
respiratory tree would exist, it would allow simulation studies in both healthy and
pathology scenarios.
In the alveoli of mammalian lungs, due to differences in partial pressures across
the alveolar-capillary membrane, oxygen diffuses out. Lungs contain a large sur-
face area to facilitate this gas exchange process. Finally, the spreading of any
quantity that can be described by the diffusion equation or a random walk model
(e.g. concentration, heat, etc.) can be called diffusion. Several factors such as:
pathologies, exercise and unusual environment can limit the gas exchange in the
lungs (i.e. limit the O2 entering the lungs). In some diseases such as emphysema
and interstitial lung disease, the capillary bed is reduced resulting in a decreased
time available for blood oxygenation. In pulmonary edema and interstitial fibro-
sis, instead, the blood-gas barrier may be thickened abnormally and the diffusing
capacity reduced. In this thesis a relation to diffusion in the lungs by means of
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mathematical modeling and non-invasive measurements is being proposed.
The second application of diffusion considered in this thesis is drug diffusion.
From the point-of-view of regulating anesthesia, mathematical modeling of drug
diffusion can be very useful to better understand the mechanism of drug delivery
systems. Therefore, the description of drug transport into the human body can be
highly beneficial and allows us to understand the insight of the mechanism and to
do quantitative prediction of the effects of formulation and processing parameters
on the resulting drug release kinetics. The major challenge in the development
or optimization of automated drug delivery systems is to achieve optimal drug
concentration at the site of action. In order to have the optimal concentration-time-
profile at the site of action the release of the drug must be controlled as accurately
as possible.
Three components define the general anesthesia state of patient: hypnosis (lack
of awareness, lack of memory), analgesia (lack of pain) and neuromuscular block-
ade (lack of movement). In literature several schemes to induce and maintain hyp-
nosis and neuromuscular blockade have been proposed. These two aspects of anes-
thesia are now mature for integration in a single environment. Hypnotic and opioid
(analgesic medication) side-effects mark changes in other biosignals as heart rate,
respiratory rate, mean arterial pressure gas in- and ex-piratory percentages, body
temperature, etc. Until recently, within the anesthesia regulation paradigm, de-
tecting and quantifying pain with an objective measure supported by means of a
mathematical model is still a missing piece in the puzzle, despite the few avail-
able monitors available just recently on the market (e.g. Medstorm, Medasense,
Algiscan). As such, pain is a complex process, involving a manifold of chemical,
physical and electrical sub-processes all sequenced in a systemic context.
In this thesis the first steps towards a sensor to measure the pain level in an
objective manner and a mathematical model to characterize nociception pathway
have been made The result is the ANSPEC-PRO monitor, non-invasively mea-
suring pain by means of skin impedance. The prototype has been validated at
this moment only in awake volunteers with self-induced nociceptor excitation (i.e.
mechanical pain stimuli). These first results will enable the next steps towards a
complete regulatory dynamic system for controlling general anesthesia by means
of its all three components: hypnosis, analgesia and neuromuscular blockade.
A brief description of the thesis outline is given hereafter.
In Chapter 1 a brief history of fractional calculus and its application in several
domains is given. The use of fractional calculus in field of biomedical engineering
is also introduced.
Chapter 2 addresses the theoretical preliminaries of diffusion phenomena in
porous media. Tools from this chapter will be further employed for the particular
cases investigated in this thesis.
In Chapter 3 a detailed description on the use of fractional calculus tools to
model the respiratory system is discussed. The diffusion concepts are discussed
from the perspective of gas exchange in the lungs and how the diffusing factor
influences the progress of disease.
In Chapter 4 a soft transition from modeling diffusion in the lungs to mod-
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eling drug diffusion is presented. Here, a detailed description of the existing
methods and tools for pain assessment along with their advantages and disad-
vantages is given. From this chapter we have concluded that no mathematically-
physiologically based model to characterize the nociceptor pathway is available.
This challenge is further addressed in Chapter 5 and 6.
Chapter 5 introduces the use of diffusion processes to characterize drug ef-
fect. To describe the evolution of drugs in the human body the compartmental
pharmacokinetic-pharmacodynamic models are used. In this chapter an analysis
of the anomalous diffusion is illustrated and a revisited pharmacokinetic model is
presented.
In Chapter 6 the first steps towards a mathematical model of nociception are
taken and a fractional order model is derived. This model has been validated on
measurements performed with the latest technology for pain assessment followed
by the obtained results. The conclusions of this thesis are presented in Chapter 7.

1
Introduction
1.1 Brief History of Fractional Calculus
Fractional calculus (FC) is an extension of ordinary calculus with more than 300
years of history. FC was initiated by Leibniz and L‘Hospital as a result of a cor-
respondence which lasted several months in 1695. The issue raised by Leibniz for
a fractional derivative (semi-derivative, to be more precise) was an ongoing topic
in decades to come. Subsequent references to fractional derivatives were made by
Lagrange in 1772, Laplace in 1812, Lacroix in 1819, Fourier in 1822, Riemann
in 1847, Green in 1859, Holmgren in 1865, Grunwald in 1867, Letnikov in 1868,
Sonini in 1869, Laurent in 1884, Nekrassov in 1888, Krug in 1890, Weyl in 1919,
and others [1, 2].
It is interesting to note that simultaneously with these initial theoretical devel-
opments, first practical applications of fractional calculus can also be found [3].
Abel’s solution had attracted the attention of Joseph Liouville, who made the first
major study of fractional calculus. Probably the most useful advance in the de-
velopment of fractional calculus was due to a paper written by G.F. Bernhard
Riemann. Unfortunately, the paper was published only posthumously in 1892.
Seeking to generalize a Taylor series in 1853, Riemann derived different defini-
tion that involved a definite integral and was applicable to power series with non-
integer exponents. The earliest work that ultimately led to what is now called the
Riemann-Liouville definition appears to be the paper by N. Ya. Sonin in 1869
where he used Cauchy‘s integral formula as a starting point to reach differentia-
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tion with arbitrary index. A. V. Letnikov extended the idea of Sonin a short time
later in 1872 [4]. Both tried to define fractional derivatives by utilizing a closed
contour. Starting with Cauchy’s integral formula for integer order derivatives.
Grunwald and Letnikov provided the basis for another definition of fractional
derivative which is also frequently used today. Today, the Grunwald-Letnikov
definition is mainly used for derivation of various numerical methods with finite
sum to approximate fractional derivatives. Among the most significant modern
contributions to fractional calculus are those made by the results of M. Caputo in
1967 [5]. One of the main drawbacks of Riemann-Liouville definition of fractional
derivative is that fractional differential equations with this kind of differential op-
erator require a rather strange set of initial conditions. Caputo [5] reformulated the
more classic definition of the Riemann-Liouville fractional derivative in order to
use classical initial conditions, the same one needed by integer order differential
equations.
1.2 Fractional Calculus in Biomedical Engineering
Fractal time series analysis, and implicitly fractional calculus, have been used to
improve the modeling accuracy of many phenomena in natural sciences [6]. The
fractional order derivative model is appropriate for modeling complex dynamics,
eg. ions undergoing anomalous diffusion in dielectrics. Fractional order models
are a generalizations of the classical integer order models. The net advantage is
that fractional differ-integration enables the inclusion of memory and hereditary
properties in models for processes governed by diffusion in all its aspects (i.e.
sub-diffusion, classical and super-diffusion).
The complexity of all living systems is expressed in the structure and function
of each cell and tissue. Thus, the biological functions of cardiac muscle, articular
cartilage and the spinal cord, for example, are embedded in the three-dimensional
structure of each tissues cells, extracellular matrix, and overall anatomical orga-
nization. In the heart, tight electrical contacts between cardiac cells ensure that
the pacemaker signals are distributed sequentially to the atria and ventricles; in the
knee, the multiple layers within hyaline cartilage distribute transient loads by the
rapid movement of ions and water; while in the axons of the spinal cord, sensory
input and reflexes are expressed via electrical signals action potentials that are
directed through complex neural networks.
For many physiological systems (e.g., action potential propagation, blood oxy-
genation, and feedback control of insulin secretion) linear differential equation
(LDE) models are highly successful. These models provide the basis for our un-
derstanding of normal physiological homeostatis, as well as the changes in system
dynamics that bring on or are the consequences of disease. Physiological models
describe events both at the molecular level (ion transport, gas diffusion, vesicle
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formation) and at the organ level (e.g. blood clearance, oxygen uptake, etc.). The
extent to which a fractional order model will span multiple scales (the nanoscale,
microscale, mesoscale, and macroscale) is based on an underlying presumption
that fractional derivatives can capture features of complex tissue structure. Cur-
rent work in fractional calculus is directed at answering the questions of where and
when such models are valid. However, the multiscale patterns observed in muscle
fibers, tendon and nerve fibers provide a structural rationale for the hypothesis that
multiscale structure is effectively encoded in fractional order operations.
The extension of linear systems to include fractional order theory requires
learning a new mathematical tool; a tool with which there are substantial issues
associated with identifying the appropriate initial conditions and in selecting the
proper definition of fractional integration to be used for a given problem [7, 8].
Relaxation processes are common in cells and tissues. Therefore, it should not be
surprising to see that fractional calculus can play an important role in describing
the input-output behavior of biological systems The physical foundations for this
behavior may be sought in the fractal or porous structure of the system components
or in the physical characteristics of its surfaces and interfaces. Much work [9] is
ongoing to develop a direct link between fractal models of molecules, surfaces,
and materials and the fractional kinetics or dynamics of the resulting behavior
(polymerization electrochemical reactions, viscoelastic relaxation).
A major attribute of fractional dynamic models is that they interpolate between
the known integer order behavior by extending the transfer function models from
rational algebraic functions of the Laplace transform parameter s to non-rational
functions f(s) involving fractional powers of sα. This is an approach that ex-
tends the traditional Laplace transform methods of linear systems analysis [10].
Hence, the fractional dynamics hypothesis is accessible to the engineer and scien-
tist through both Laplace and Fourier techniques (for s = jω where j =
√−1 and
ω is the angular frequency in rad/s).
Diffusion plays an important role in many processes in living organism, is a
key feature in the course of drug distribution in the human body. The research per-
formed in the last decades suggest diffusion processes can deviate from Fick’s first
law. They can be either faster (super-diffusion) either slower (sub-diffusion) pro-
cesses [11, 12]. This new approach of diffusion processes is described as anoma-
lous diffusion. In biomedical literature several datasets have been characterized
by power-laws [13], gamma functions or fractal kinetics [11, 12], and their use
has been justified by the presence of the anomalous diffusion. It has been shown
that fractional calculus is an alternative theory that can describe this anomalous
behavior [11–13]. In the past many attempts to model the diffusion process have
been made and fractional order models have been shown to well-characterize these
processes. The last decade has shown an increased interest in the research commu-
nity to employ parametric model structures of fractional order (FO) for analyzing
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nonlinear biological systems [11, 12, 14, 15]. The advantage of using tools from
fractional calculus over the standard integer order modeling approaches is that it
can describe very well the inherent abnormal or heavy tail decay processes.
1.3 Contributions of this thesis
In this thesis the diffusion process will be addressed from the perspective of two
applications: diffusion of gas exchange in the lungs and drug diffusion. Diffusion
is of fundamental importance in many disciplines of physics, chemistry and biol-
ogy. It is well known that the fractional operator d
0.5
dt0.5 ←→ s0.5 appears in several
types of problems [16, 17]. The transmission lines or the heat flow are examples
where the half-operator is the fundamental element. Diffusion is in fact part of
transport phenomena, being one of the essential partial differential equations of
mathematical physics. Molecular diffusion is generally superimposed on, and of-
ten masked by, other transport phenomena such as convection, which tend to be
much faster. However, the slowness of diffusion can be the reason for its impor-
tance. Transport due to diffusion is slower over long length scales: the time it
takes for diffusion to transport matter is proportional to the square of the distance.
In cell biology, diffusion is the main form of transport for necessary materials such
as amino acids within cells. Metabolism and respiration rely in part upon diffusion
in addition to active processes.
In the alveoli of mammalian lungs, due to differences in partial pressures across
the alveolar-capillary membrane, oxygen diffuses out. Lungs contain a large sur-
face area to facilitate this gas exchange process. Finally, the spreading of any
quantity that can be described by the diffusion equation or a random walk model
(e.g. concentration, heat, etc.) can be called diffusion. Several factors such as:
pathologies, exercise and unusual environment can limit the gas exchange in the
lungs (i.e. limit the O2 entering the lungs). In some diseases such as emphysema
and interstitial lung disease, the capillary bed is reduced resulting in a decreased
time available for blood oxygenation. In pulmonary edema and interstitial fibrosis,
instead, the blood-gas barrier may be thickened abnormally and the diffusing ca-
pacity reduced. If the diffusion coefficient decreases, oxygen diffusion is impeded
and as a consequence the rise in partial pressure when oxygen enters a red blood
cell is slowed down. In both situation, the partial pressure of oxygen may not reach
that of alveolar gas before the end of the pulmonary capillary.
Diffusion in lungs can be also stressed by a decrease of the alveolar oxygen
partial pressure, e.g. when the subject reaches high altitude or breathes a low oxy-
gen mixture. In fact, this reduces the partial pressure difference responsible for
driving the oxygen across the blood-gas barrier. Moreover, during exercise, the
pulmonary blood flow increases, causing pulmonary capillary transit time to fall.
For example, during severe exercise the time spent by the red cell in the pulmonary
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capillaries may be brought down to as little as one-third, resulting in a reduced time
for oxygenation. Despite this, in healthy subjects, breathing normal air, the fall in
the end-capillary is generally not measurable. However, if the blood-gas barrier
of the subject is considerably thickened by disease the difference between alveo-
lar and end-capillary is noticeable. For instance, chronic obstructive pulmonary
disease (COPD), defined by airflow limitation, is associated with an important re-
duction in physical activity. This leads to patient’s disability an poor health-related
quality of life. Diffusing capacity for carbon monoxide is a common clinical test
that provides a quantitative measure of gas transfer in the lungs. A decrease in
diffusing capacity (one of the first signs of disease progression) indicated arterial
oxygen desaturation during exercise. In case of subjects with COPD a decrease in
diffusing capacity poses a high risk for poor survival.
The main contribution on this first application is a relation to diffusion in the
lungs by means of mathematical modeling and non-invasive measurements. The
main results are presented in Chapter 3.
The second application of diffusion considered in this thesis is drug diffusion.
From the point-of-view of regulating anesthesia, mathematical modeling of drug
diffusion can be very useful to better understand the mechanism of drug delivery
systems. Therefore, the description of drug transport into the human body can be
highly beneficial [18–20] from two points-of-view: (i) allows you to understand
the insight of the mechanism and (ii) allows you to do quantitative prediction of
the effects of formulation and processing parameters on the resulting drug release
kinetics. The major challenge in the development or optimization of automated
drug delivery systems is to achieve optimal drug concentration at the site of action.
In order to have the optimal concentration-time-profile at the site of action the
release of the drug must be controlled as accurately as possible.
Diffusion phenomena has been extensively investigated in the last years in the
field of drug delivery systems. One of the most common methods to describe the
diffusion phenomena of drug in the human body is the compartmental modeling.
This analysis is based on mathematical models, typically in the form of systems of
ordinary differential equations that are widely used to characterize the time of up-
take and elimination of a drug. Diffusion represents a key process in the uptake of
drugs by the human body. Processes such as membrane permeability, dissolution
of solids and dispersion in cellular matrices are considered to be governed by diffu-
sion [12,15]. It has been observed that faster processes (super-diffusion) or slower
processes (sub-diffusion) can be modeled by fractional-order derivatives with an
order greater or less than 1, respectively. It has been shown that differential equa-
tions with fractional derivatives and integrals describe anomalous diffusion more
accurately [21, 22].
The main contribution on the second application investigated in this thesis is a
proof that pharmacokinetic-pharmacodynamic drug diffusion models are charac-
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terized by memory effects. This justifies the use fractional order tools to model
these processes. The results obtained are presented in Chapters 5 and 6.
1.4 Thesis outline
In this thesis the use of fractional calculus tools with applications to respiratory
system and nociception pathway modeling is addressed. The outline of the thesis
is presented hereafter:
In Chapter 1 a brief history of fractional calculus and its application to sev-
eral domains is given. Next, a more detailed description on the use of these tools
in biomedical engineering is provided. In this chapter the importance and the ad-
vantages of using fractional calculus tools to describe complex phenomena (e.g.
diffusion) is introduced. The main contributions of this thesis along with the re-
lated list of publication are also given.
In Chapter 2 the preliminaries on diffusion theory are presented. Here, the
mathematical concepts and definition of diffusion through porous media are ad-
dressed. Based on the focus of this thesis, three modelling approaches are consid-
ered: i) longitudinal diffusion, spherical diffusion and molecular diffusion. The-
oretical concepts introduced in this chapter, will be further used to characterize
diffusion of gas in human lung and drug diffusion in the human body.
In Chapter 3 a detailed description on the use of fractional calculus tools to
model the respiratory system is addressed. The diffusion concepts are discussed
from the perspective of gas exchange in the lungs and how the diffusing factor in-
fluences the progress of disease. Based on the theory presented in previous chapter
a fractional order impedance model has been derived. First, the impedance for one
alveolus has been simulated followed by a network of alveoli. The main contri-
bution in this chapter is a first link between diffusion phenomena in the lungs and
chronic obstructive pulmonary disease, by means of mathematical models. Pa-
rameters such as tissue damping (reflecting the capacity for energy absorption)
and tissue hysteresivity have been used to investigate if there is a link between
changes in small airways and the diffusion phenomena.
In Chapter 4 a soft transition from modeling diffusion in the lungs to mod-
eling drug diffusion is presented. Here, a detailed description of the existing
methods and tools for pain assessment along with their advantages and disad-
vantages is given. In clinical practice, the most used tool for pain assessment
(for communicative patients) are the numerical and visual rating scales. For the
non-communicative patients several attempts to develop a tool to evaluate pain
have been made. Despite the advances in pain research and management, the
assessment of pain in an objective way (for both cases, communicative and non-
communicative patients) remains a challenge. In the last years, a few devices
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have been developed towards an objective assessment of pain, but there is not
enough clinical validation of these devices and therefore they are not part of the
daily clinical routine. Moreover, from this chapter we have concluded that no
mathematically-physiologically based model to characterize the nociceptor path-
way is available. This challenge is further addressed in Chapter 5 and 6.
In Chapter 5 an introduction on the use of diffusion processes to characterize
drug effect is given. To describe the evolution of drugs in the human body the com-
partmental pharmacokinetic-pharmacodynamic models are used. In this chapter a
preliminary step towards a nociceptor pathway model is presented. Understanding
and characterizing the drug transport (diffusion) in the human body allows us to
understand the insight of the diffusion process and provides us a way to predict
the effects on the drug release kinetics. When a drug (for pain relief) is given to
a patient the nociception is inhibited. Understanding phenomena such as drug up-
take, distribution and elimination will give extra insight which can be further used
in developing a mathematical model of nociception. In this chapter an analysis
of the anomalous diffusion is illustrated and a revisited pharmacokinetic model is
presented.
In Chapter 6 the first steps towards a mathematical model of nociception are
taken and a fractional order impedance model is derived. For validation purposes
an in-house prototype device for continuous measurement of skin impedance has
been developed. This custom-made device allows us to excite the skin with an
multisine as an input signal (i.e. sending in a voltage) and measuring the corre-
sponding output (i.e. the current). A brief description of the device is given in
Appendix A. In this chapter four mathematical models have been investigated
(i.e. Cole-Cole impedance model, non-parametric impedance model, interlaced
zero-pole impedance model and the developed lumped fractional order impedance
model) and validated using the developed device for pain assessment.
In Chapter 7 the conclusions of this thesis are presented followed by the future
perspectives beyond this doctoral thesis.
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2
Preliminaries on Diffusion
This Chapter introduces the necessary definitions and mathematical preliminaries
on diffusion phenomena through porous media. The use of fractional calculus tools
to model diffusion processes is also introduced. The theoretical aspects addressed
here are the basis for the remainder of this thesis.
2.1 Fractional order modelling of diffusion through
porous media
Most of the natural laws of physics (e.g. Newton’s law, Maxwell’s law, Fick’s law,
Fourier’s law) are stated in terms of partial differential equations (PDE). These
laws characterize the physical phenomenon by means of balance (energy, mass,
heat) equations. The basic process in the diffusion phenomenon is the movement
of fluid (or ions, or air) from a zone with a higher density (concentration, pres-
sure) to one of lower. In a diffusion process or a chemical reaction Fick’s law
provides a linear relationship between the flux of molecules and the chemical po-
tential difference. Likewise, there is a direct relation between the heat flux and the
temperature difference in a thermally conducting slab, as expressed by Fourier’s
law. For example, diffusion of gases between the air in the lungs and blood takes
place from a region with a higher concentration to one with a lower concentration.
As the difference in concentration increases also the diffusion rate is increasing.
Material properties of tissue arise from nanoscale and microscale architecture of
sub-cellular, cellular and extracellular networks. Previous works concerning diffu-
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Figure 2.1: Schematic representation of diffusion through a wall.
sion modelling using fractional calculus approach have already shown the ability
of such models to estimate with good accuracy the frequency behavior from time
data acquisitions [16, 17, 23, 24]. In the following sections three modelling ap-
proaches are addressed.
2.1.1 Longitudinal diffusion modelling
Let us consider the problem which consists in computing the heating temperature
Tin(t) at the front face of a wall where a random heat flux Pin(t) is applied.
Heating temperature T (x, t) is assumed to be uniform on any plane parallel to the
front and back face (see Figure 2.1). The dimensions of the wall are characterized
by its section Sw and thickness L. Let P (x, t) be the flux passing through the wall
at abscissa x. T (x, t) and P (x, t) satisfy the following heat diffusion equations:
∂T (x, t)
∂t
= a
∂2T (x, t)
∂x2
(2.1)
P (x, t) = −λSw ∂T (x, t)
∂x
(2.2)
with:
• λ - thermal conductivity (Wm−1 oC−1),
• a = λ/ρc - thermal diffusivity (m2 s−1),
• ρ - mass density (kgm−3),
• c - specific heat (J kg−1 oC−1).
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Let Tout(t) be the back face temperature and Pout(t) the output flux. We write
Tin(s), Pin(s) and Tout(s), Pout(s) the Laplace transforms of Tin(t), Pin(t) at
x = 0 and Tout(t), Pout(t) at x = L. One can model the wall using a thermal
quadrupole relating the inputs (Tin(s), Pin(s)) to the outputs (Tout(s), Pout(s))
[25]: [
Tin(s)
Pin(s)
]
=
[
A B
C D
]
∗
[
Tout(s)
φout(s)
]
(2.3)
where the matrix coefficients A, B, C, D characterize the heat transfer phe-
nomenon in the wall. By applying the Laplace transform to (2.1) and (2.2), one
obtains:
sT (x, s)− T (x, 0) = a∂
2T (x, s)
∂x2
(2.4)
P (x, s) = −λSw ∂T (x, s)
∂x
(2.5)
Assuming the longitudinal temperature profile is initially constant at time t = 0:
T (x, 0) = 0, 0 < x < L (2.6)
The solution set of the second order spatial differential equation (2.4) is given by:
T (x, s) = L1(s)cosh(δx) + L2 sinh(δx) (2.7)
with δ =
√
s/a. Using (2.5) and (2.7) and considering the boundary conditions
yields to:
Tin(s) = cosh(δL)Tout(s) +
1
λSw
sinh(δL)
δ Pout(s)
Pin(s) = λSwδ sinh(δL)Pout(s)
(2.8)
Hence the wall thermal matrix coefficients are given by:
A = D = cosh(δL)
B = 1λSw
sinhδL
δ
C = λSwδ sinh(δL)
(2.9)
If we consider the experiment where the back-face temperature is kept constant
(i.e. Tout(s) = 0), the transfer function which can be interpreted as thermal
impedance is:
Zw(s) =
Tin(s)
Pin(s)
=
B
D
=
L
λSw
tanh(λL)
δL
=
L
λSw
tanh(
√
s
aL)
(
√
s
aL)
(2.10)
The static gain of that transfer function corresponding to the thermal resistance
Rthw has the following expression:
lim
s→0
Zs(s) =
Tf (s)
Pin(s)
= Rthw =
L
λSw
(2.11)
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At high frequencies, the the wall behaves half order integrator:
lim
s→∞Zs(s) =
√
a
λSws0.5
(2.12)
2.1.2 Spherical diffusion modelling
Let us consider the problem which consists in computing the heating temperature
Tin(t) at the inner surface of a sphere of radius r1 where the random heat flux
Pin(t) is applied. Heating temperature T (r, t) is assumed to be uniform on any
spherical slice of radius r (see Figure 2.2). Let φ(r, t) be the flux passing through
the sphere at radius r. Assuming the heat conduction is isotropic, the heat diffusion
is an unidirectional phenomenon governed by the following equations:
Figure 2.2: Schematic representation of diffusion through a sphere.
∂T (r, t)
∂t
= a
[
∂2T (r, t)]
∂r2
+
2
r
x
∂T (r, t)
∂r
]
(2.13)
φ(r, t) = −λ(4pir2)∂T (r, t)
∂r
(2.14)
with λ; a; ρ and c defined in Section 2.1.1.
Let Tout(t) be the outer temperature and φout(t) the output flux. We write the
Tin(s), Pin(s) and Tout(t), φout(t) the Laplace transforms of Tin(t), Pin(t) at
r = r1 and Tout(t), φout(t) at r = r2. One can model the wall using a quadrupole
relating the inputs (Tin(s), Pin(s)) to the outputs (Tout(s), φout(s)).[
Tin(s)
Pin(s)
]
=
[
A B
C D
]
∗
[
Tout(s)
φout(s)
]
(2.15)
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where the matrix coefficients A, B, C and D characterize the heat transfer phe-
nomenon in the sphere. Applying the Laplace transform to (2.13) and (2.14) pro-
vides:
sT (r, s)− T (r, 0) = a
[
∂T (r, s)
∂r2
+
2
r
x
∂T (r, s)
∂r
]
(2.16)
φ(r, s) = −λ(4pir2)∂T (r, s)
∂r
(2.17)
Assuming the radial temperature profile is initially constant at time t=0:
T (r, 0) = 0, r1 < r < r2 (2.18)
The solution of the second order partial differential equation (2.16) is given by:
T (r, s) = r−0.5x
[
L1(s)I−0.5(δr) + L2(s)K−0.5(δr)
]
(2.19)
with δ =
√
s/a.
L1(s) and L2(s) are constant of integration and I−0.5(x) and K−0.5(x) are
modified Bessel functions of, respectively, first and second type given by [26]:
K−0.5(x) =
( pi
2x
)0.5
e−x (2.20)
I−0.5(x) =
( 2
pix
)0.5
(2.21)
Considering the boundary conditions and using equations (2.19) and (2.17) the
matrix terms A, B, C and D characterizing the heat transfer of the sphere can be
determined [27]:
A = r1r2 cosh(δ(r2 − r1))−
sinh(δ(r2−r1))
δr1
B = 14pir1r2
sinh(δ(r2−r1))
δλ
C = 4pir2λ[1− r1r2 cosh(δ(r2 − r1)) + (λr1 − 1λr2 )
sinh(δ(r2−r1))
δr1
D = r1r2 cosh(δ(r2 − r1)) +
sinh(δ(r2−r1))
δr1
(2.22)
Considering that the heat flux Pin(t) is applied uniformly to the inner spherical
surface of radius r1, the output temperature of the external spherical surface r2
being kept constant (Tout(s) = 0), the following transfer function which can be
interpreted as a thermal impedance is obtained:
Zs(s) =
Tin(s)
Pin(s)
=
B
D
=
(
1
4pir1λ
)
1
1 +
√
s
ar1
1
tanh(
√
s
a (r2−r1))
(2.23)
The thermal resistance Rths is given by considering the static gain:
lim
s→0
Zs(s) =
Tin(s)
φin(s)
= Tths =
1
4piλ
[
1
r1
− 1
r2
]
(2.24)
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At high frequencies, the thermal impedance of the sphere behaves like a non-
integer integrator whose order is equal to 0.5:
lim
s→∞Zs(s) =
√
a
λ(4pir2i )s
0.5
(2.25)
2.1.3 Molecular diffusion
In this section a general approach for modelling a system consisting of identical
or different species is given. Through its alveolar nature, a specie consists of an
orifice and a cavity. The orifice serves as hydraulic resistance or energy dissipater
or dashpot. The cavity serves as pneumatic capacitance or energy tanks or spring.
By analogy, a resistance-capacitance cell can represent the specie model.
Case of identical species: A first step considering identical species, the aim
being to study the structuring effect of multiplicity. As all the species are identical
(Figure 2.3), each specie absorbs same flow. The transition from one specie to
N species shifts the model from a RC cell (Figure 2.3) to a new RC cell (Figure
2.4) whose resistance is N times lower than for a single specie (R/N ) and has a
capacitance N time higher than for a single specie (NC).
Figure 2.3: Schematic of a RC model for identical species.
Figure 2.4: Transition from one specie to N species.
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Case of different species: A second step consists in considering the different
species (Figure 2.5), the aim being to study the structuring effect of difference as-
sociated with multiplicity. The species are differentiated through their orifices and
cavities. Therefore, the resistance and capacitance characterizing them exhibits a
constant ratio of the recursive factors (α and η). An RC cell network is character-
Figure 2.5: Schematic of a RC model for different species.
ized by an admittance (Y (jω)) given by (2.26) whose Bode diagram is shown in
Figure 2.6
Y (jω) = jω
∑
i
Ci
1 + CiRijω
(2.26)
with Ri = Rαi and Ci =
C
ηi
with their recurrent ratios. As described in [28] the
Bode diagrams can only take the average of asymptotic diagrams (Figure 2.6).
From here also the idea of smoothing of the steps for gain and the crenels for the
phase. The smoothing of the steps is represented by a gain smoothing line with the
slope less than 20 dB/dec and with 0 < m < 1. The smoothing of the crenels is
characterized phase smoothing line with an order less than pi/2 with 0 < m < 1,
with m = logα/log(αη). Considering the studied system presented in Figure 2.7
and from Newton’s second law one may write the following differential equation:
M
dV (t)
dt
+ F (t) = 0 (2.27)
where V (t) is the speed of mass M and F (t) is the dyke reaction force. If S is
the flow section V (t) = Q(t)/S and F (t) = P (t)S. Hence, the new differential
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Figure 2.6: Smoothing of the Bode diagrams.
Figure 2.7: Study system.
equation with two variables Q(t) and P (t):
M
S2
dQ(t)
dt
+ P (t) = 0 (2.28)
Finally, the water-dyke admittance can be described by the following equation:
Y (jω) =
Q(jω)
P (jω
=
(
jω
jω0
)m
(2.29)
for which is deduced the symbolic equation:
Q(jω) =
1
ωm0
(jω)mP (jω) (2.30)
which, in time domain, is expressed as:
Q(t) =
1
ωm0
(
d
dt
)m
P (t) (2.31)
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This equation represents the (dynamic) model of the porous interface and in-
dicates that the flow Q(t) is proportional to the non-integer derivative of pressure
P (t).
2.2 Summary
This Chapter presented the theoretical aspects of diffusion processes. The theoret-
ical aspects addressed in this chapter of the thesis are further employed to model
the diffusion of gases in the lungs and drug diffusion in the human body. Diffu-
sion in lungs is addressed in Chapter 3 and the tools presented in this chapter are
employed to model the gas exchange phenomena. For this, the theory presented
here is used in order to model a network of alveoli. Both cases (i.e. identical
and different species/alveoli) presented in this section are used to model the dif-
fusion process. Modelling of drug diffusion in the human body can be also mod-
eled using the tools presented in this chapter. More specifically, in Chapter 5 the
pharmacokinetic-pharmacodynamic model characterizing drug uptake and effect
are based on theoretical aspects presented in this chapter.

3
Diffusion in the Lungs
In this Chapter the importance of gas diffusion through the respiratory membrane
is investigated. The theory described in Chapter 2 is further employed in Section
3.4. First, the impedance of one alveolus has been simulated followed by a net-
work of alveoli. The simulation results are then compared with measurements by
means of derived parameters.
The main publications where this work has been presented are:
• D. Copot, C.M. Ionescu, R. De Keyser. Structural changes in the COPD
lung and related changes in diffusion mechanism, PLOS ONE Journal, 12(5),
doi.org/10.1371/journal.pone.0177969, 2017.
• D. Copot, C.M. Ionescu, R. De Keyser. Relation between fractional order
models and diffusion in the body, IFAC World Congress, Cape Town, South
Africa, 24-29 August, 9277-9282, 2014.
• C.M. Ionescu, D. Copot, R. De Keyser. A fractional order impedance model
to capture the structural changes in lungs, IFAC World Congress, Cape
Town, South Africa, 24-29 August, 5363-5368, 2014.
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3.1 Lung mechanics
Breathing is essentially a mechanical process in which the muscles of the thorax
and abdomen, working together under the control of the brain, produce the pres-
sures required to expand the lung so that air is sucked into it from the environment.
These pressures must be sufficient to overcome the tendencies of the lung and chest
wall tissues to recoil, much like blowing up a balloon. Pressure is also required to
drive air along the pulmonary airways, a system of branching conduits that begins
at the mouth and ends deep in the lungs at the point where air and blood are close
enough to exchange oxygen and carbon dioxide. The mechanical properties of the
lungs thus determine how muscular pressures, airway flows, and lung volumes are
related. The research field of lung mechanics is concerned with the study of these
properties [29].
In a spontaneously breathing subject, a negative pressure is generated around
the outside of the lungs by the respiratory muscles. This produces a flow of gas
along the pulmonary airways in the direction of decreasing pressure. The blood-
gas barrier is less than a micron thick, so it presents a very small impediment to
the passage of gas molecules. It also has an extremely large surface area so that
many gas molecules can cross it in parallel. The transport of oxygen and carbon
dioxide across the blood-gas barrier occurs solely by passive diffusion. Gases
always tend to move from regions of high partial pressure to regions of low partial
pressure. The partial pressures of oxygen and carbon dioxide in the alveoli and the
pulmonary capillary blood normally favor movement of oxygen into the blood and
carbon dioxide into the alveoli. The blood-gas barrier that these gases must cross
in the process is so large and so thin that sufficient numbers of gas molecules can
move across it to meet the demands of life in a healthy lung. In some diseases,
however, this ceases to be the case. The efficiency of gas exchange is thus tightly
linked to the physical properties of the blood-gas barrier.
3.2 Gas Diffusion Through the Respiratory Mem-
brane
There are about 300 million alveoli in the two lungs, and each alveolus has an
average diameter of about 0.2 millimeter. The alveolar walls are extremely thin,
and between the alveoli is an almost solid network of interconnecting capillaries.
The thickness of the respiratory membrane occasionally increases for instance, as
a result of edema fluid in the interstitial space of the membrane and in the alveoli
so that the respiratory gases must then diffuse not only through the membrane but
also through this fluid. Also, some pulmonary diseases cause fibrosis of the lungs,
which can increase the thickness of some portions of the respiratory membrane.
Because the rate of diffusion through the membrane is inversely proportional to
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the thickness of the membrane, any factor that increases the thickness to more than
two to three times the normal can interfere significantly with normal respiratory
exchange of gases.
The diffusion coefficient for transfer of each gas through the respiratory mem-
brane depends on the gass solubility in the membrane and, inversely, on the square
root of the gass molecular weight. The rate of diffusion in the respiratory mem-
brane is almost exactly the same as in water. Therefore, for a given pressure dif-
ference, carbon dioxide diffuses about 20 times as rapidly as oxygen. Oxygen
diffuses about twice as rapidly as nitrogen. The pressure difference across the res-
piratory membrane is the difference between the partial pressure of the gas in the
alveoli and the partial pressure of the gas in the pulmonary capillary blood. The
partial pressure represents a measure of the total number of molecules of a partic-
ular gas striking a unit area of the alveolar surface of the membrane in unit time,
and the pressure of the gas in the blood represents the number of molecules that
attempt to escape from the blood in the opposite direction.
Diffusing Capacity for Oxygen. In the average young man, the diffusing ca-
pacity for oxygen under resting conditions averages 21 ml/min/mm Hg. In func-
tional terms, means that the mean oxygen pressure difference across the respiratory
membrane during normal, quiet breathing is about 11 mm Hg. Multiplication of
this pressure by the diffusing capacity (11x21) gives a total of about 230 milliliters
of oxygen diffusing through the respiratory membrane each minute;this is equal to
the rate at which the resting body uses oxygen.
Diffusing Capacity for Carbon Dioxide. The diffusing capacity for carbon
dioxide has never been measured because of the following technical difficulty:
Carbon dioxide diffuses through the respiratory membrane so rapidly that the av-
erage Pco2 in the pulmonary blood is not far different from the Pco2 in the alve-
olithe average difference is less than 1 mm Hg and with the available techniques,
this difference is too small to be measured. Nevertheless, measurements of dif-
fusion of other gases have shown that the diffusing capacity varies directly with
the diffusion coefficient of the particular gas. Because the diffusion coefficient of
carbon dioxide is slightly more than 20 times that of oxygen, one would expect a
diffusing capacity for carbon dioxide under resting conditions of about 400 to 450
ml/min/mm Hg and during exercise of about 1200 to 1300 ml/min/mm Hg.
In Figure 3.1 the gas exchange in the blood capillaries of the lungs and systemic
circulation is shown. As a result of gas exchange in the lungs, the systemic arteries
carry oxygenated blood with a relatively low carbon dioxide concentration. After
the oxygen is unloaded to the tissues, the blood in the systemic veins has a lowered
oxygen content and an increased carbon dioxide concentration.
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Figure 3.1: Gas exchange in the blood capillaries of the lungs and systemic circulation.
3.3 Structural changes in chronic obstructive pul-
monary disease
COPD is often paired with emphysema and referred to as small airway disease
[30, 31]. It features a prolonged time constant for lung deflation, due to increased
resistance of the small conducting airways and increased compliance as a result
of emphysematous destruction. The latter implies breaking the alveolar walls
and disruption of the adjacent connective walls, inflammation and tissue mass en-
largement. Density of the lung is decreased, with airspace enlargement and com-
puter tomography scans have shown various degrees of heterogeneity in density of
porous tissue with various degrees of obstruction [32].
Using a gross analogy to the Sierpinski triangle of various densities, as illus-
trated in Figure 3.2, we can enumerate the following changes in our impedance
model as a result of airway remodelling in COPD:
• the R and C parameters, along with their corresponding recurrent ratios,
will vary in different respiratory zones;
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Figure 3.2: Classical Sierpinski triangle (left) and Sierpinski-like arrangement of alveolar
areas with various degrees of density.
• the alveolar changes will affect the fractional order term value n;
• within respiratory zones, different such fractional order term values will ex-
ist;
• the porous structure of the network of alveoli will then contain multi-fractal
spacial distribution and thus multi-fractal dynamics.
Fractal and multi-fractal analysis has been given lots of attention in medical ap-
plications [33]. Specifically for lung applications, dissimilarity principle has been
applied to classify lung parenchyma based on image processing techniques [34],
as well as pulmonary emphysema [35]. Airway remodelling has been correlated
to fractal dimension in asthma [36], providing insight into space filling mecha-
nism. Pulmonary embolism has been detected using multifractal analysis from
lung scans and provided useful classification tool [37].
It is interesting to provide a correlation between changes in COPD at the alve-
olar level and fractional order impedance values evaluated in various degrees of
obstruction. As COPD progresses, changes in the R,C parameters and structure
of the alveolar network will affect the impedance and thus the lung function will
change.
As the ratios of resistance and capacitance increase with various degrees of
COPD obstruction (i.e. classified as GOLD2, GOLD3 and GOLD4, from mild to
severe degree of obstruction), the fractional order term value n will vary. If the
relative increase is the same, the value will remain unchanged. If resistance has
absolute variance higher than capacitance, then the values of n will increase. Sim-
ilarly, if capacitance has absolute variance higher than resistance, then the values
of n will decrease.
The implications for damping are complex. Due to relative increase in com-
pliance as a result of more empty spaces in the alveolar structure, damping will
apparently decrease, but due to increased tissue density, the overall damping is
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increasing. Notice that if alveolar surface is decreased with pathology, the time
constant defined in previous section for the network will also increase. This is in
line with the pathology of COPD which has long deflation periods. In conclusion,
local structural changes are more important than the network spacial distribution
in terms of impedance.
3.4 Diffusion at low frequencies
In the context of electrical analogy, one usually considers voltage as the equivalent
for respiratory pressure (P ) and current as the equivalent for airflow (Q). The
pressure in function of time is the accumulation of these components with the
trans-pulmonary pressure at end-expiration (P0):
P (t) =
1
C
V (t) +R
dV
dt
+ I
d2V
dt2
+ P0 (3.1)
where elastance (1/C) (the reciprocal of the compliance) is directly related to
volume (V ), the resistance (R) is related to airflow and the inertia (I) is related
to accelerating particles. This equation represents the global relationship between
airflow and pressure in the lungs. Its equivalent frequency domain form is the
respiratory impedance as a function of oscillatory frequency [38].
This principle has been applied by means of Womersley theory and Navier-
Stokes equations to elastic tubes preserving structure and morphology of the air-
ways [39]. According to the seminal work of Weibel and Mandelbrot [40–42], the
structure of the lungs can be roughly approximated by a recurrent dichotomous
tree of 24 levels, leading to a rough approximation of 224 alveolar ducts. At the
end of each alveolar duct there is a porous bag called alveoli, which are grouped
together like a lot of interlinked caves, rather than individual sacks.
A mathematical model of the respiratory tree up to 24th level has been pro-
posed [39] and used in subsequent works in clinical studies [14]. The model is
based on the geometrical parameters: radius and wall thickness (r, h), on the me-
chanical characteristics of the airway tube: complex elastic moduli (given by its
modulus (|E|) and angle(ϕE)) on the Poisson coefficient (νP ), and on the air prop-
erties: viscosity and density (µ, ρ). Over the length ` of an airway tube, we have
the corresponding definitions for electrical resistance:
Re = `
µδ2
pir4M1
sin(ε1), (3.2)
and for electrical capacitance
Ce = `
2pir3(1− ν2P )2
|E|h cosϕE , (3.3)
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where, M1 is the modulus of the Bessel function of order 1, ε1 is the phase an-
gle of the complex Bessel function of order 1, and δ =
√
ωρ/µ the Womersley
parameter.
We have shown that the geometry of the lungs leads to a piecewise fractal
structure, whose electrical equivalent leads to a recurrent ladder network. The
admittance of such network has the form:
YN (s) ∼= 1/Re1
1 +
1/Re1Ce1s
1 +
1/γRe1Ce1s
. . .
. . .
1 +
1/χN−2γN−1Re1Ce1s
1 + 1/χN−1γN−1Re1Ce1s
(3.4)
with Re1 and Ce1 denoting the resistance and compliance in the first airway (i.e.
trachea), and γ the ratio of resistances per total levels, χ the ratio of compliances
per total levels and s the Laplace operator. This continuous fraction expansion
can be well-approximated for N → ∞ airway levels by the compact form of
admittance [43]:
YN (s) ∼= 1/Re1
K(γ, χ) · (1/Re1Ce1s)n (3.5)
with K(λ, χ) a gain factor depending on the values of the ratios and the fractional
order n given by
n =
log(γ)
log(γ) + log(χ)
(3.6)
Notice that the impedance, ZN (s) will be the inverse of the admittance. In the
frequency domain, the fractional order will lead to a constant-phase behaviour, i.e.
a phase-locking in the frequency range given by the convergence conditions [14,
43]. The lumped version of this model is the well-known constant-phase element
model given by:
ZCP (sk) = R+ I(sk) +
1
C(sβk)
(3.7)
where R (kPa s/L) and I (kPa s2/L) denote the central airway resistance and in-
ertance respectively, whereas the last term consists of a constant-phase element
which can be split into a real and imaginary part, denoting tissue damping and
tissue elastance. These two latter properties are defined as averaged over the fre-
quency range evaluated by the lung function test [44–46].
Gr =
1
Cωβk
cos(βpi/2)
Hr =
1
Cωβk
sin(βpi/2)
ηr =
Gr
Hr
(3.8)
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and their ratio denotes the degree of heterogeneity present in the tissue [47]. This
ratio is in fact a characterization of sources for nonlinear contributions in the res-
piratory dynamical properties. If changes in R are small, then any changes in Gr
(kPa s(1−β)/L) will represent changes in parenchyma or in very small airways.
The memory effects are introduced via s(1−β) [16]. These effects are observed
in materials with viscoelastic properties. Chronic changes in Hr (kPa s(1−β)/L)
reflect changes in the intrinsic mechanical properties of the parenchyma [48]. This
parametric model has been shown to reliably estimate airway and tissue proper-
ties and its sensitivity to bronchodilatation in dogs at low frequencies has been
assessed in [44]. The same model has been used to assess respiratory impedance
in rats at low frequencies in [49]. The model has been used to evaluate respiratory
impedance in healthy and sick patients [14, 47]. The reliability of the parameter
estimates from model fitting to raw data has shown that the inertance I and the
resistance R may contain a high degree of uncertainty , while the constant-phase
term delivers a reliable estimate of peripheral tissue properties. The study also
showed that the steep dependency on frequency at low frequencies in the real part
of impedance is consistently fitted by the constant-phase model from (3.7) when
compared to other models from literature.
In order to quantify the non-linear contributions the following index has been
introduced [14]:
T =
Peven + Podd
Pexc
· Uexc
Ueven + Uodd
(3.9)
where each variable represents the sum of the absolute values of all the contribu-
tions in the pressure and flow signals a non-excited frequencies (even and odd) and
the odd excited frequencies. The index expresses the relative ration of the contri-
butions at non-excited frequencies with respect to the contributions at the excited
frequencies. For a detailed overview on filtering techniques applied to extract the
contributions see [14, 50].
To allow a systematic approach, we need to use an impedance model of one
alveolus which will be later used for analysis of alveolar sac structures and their
respective properties in presence of remodelling effects.
Impedance of one alveolus: Let us assume a spherical alveolus characterized
by an inner radius r1 and an outer radius r2. We may assume without loss of
generality that heat conduction is anisotropic, heat diffusion is unidirectional and
spherical coordinates can be used for modelling. Following the line of thought
presented in [16, 17], approximating the spherical wall (i.e. difference between
inner radius and outer radius) with many cells whose pressure is governed by:
dPi
dt
=
1
RiCi
(Pi−1 − 2Pi + Pi+1) (3.10)
with Ri and Ci representing the resistance and compliance properties of the cell
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i and Pi pressure profile assumed uniformly distributed along the cell face. The
thickness of each cell is then given by the relation: h = r2 − r1/N , with N the
total number of cells and 0 ≤ i ≤ N . Introducing N0 = r1/h, it follows that the
radii of each cell is given by ri = (N0 + i)h. The surface of the cell becomes:
Si = 4pir
2
i = 4pih
2(N0 + i)
2 (3.11)
and it follows that the resistance of each cell is given by:
Ri =
h
λ · Si =
1
4piλh(N0 + i)2
(3.12)
where λ is the thermal conductivity (W m−1 o C−1). The capacity per cell is
defined as:
Ci =
4
3
pih3[3(N0 + i)
2 +
1
4
]ρc (3.13)
with ρ mass density (kg m−3) and c specific heat (J kg−1 oC−1). The ladder
network of series connected cells with resistance and capacity calculated in (3.12) -
(3.13) in Laplace operator, provides the explicit impedance which can be evaluated
over a range of frequencies. This can be either a ladder network made of recurrent
elements, either one with same element values per cell. In our case, the latter
applies since we assumed a homogeneous density of the alveolar wall.
Numerical simulation was performed using a linear state-space representation
given in (3.14)-(3.15):
As(i, i− 1) = a
h2
(N0 + i)
2
(N0 + i)2 +
1
12
As(i, i) = − a
h2
(N0 + i)
2 + (N0 + i+ 1)
2
(N0 + i)2 +
1
12
As(i, i− 1) = a
h2
(N0 + i+ 1)
2
(N0 + i)2 +
1
12
(3.14)
As(1, 1) =
a
h2
(N0 + 1)
2
N20
2 +
N0
2 +
1
24
As(1, 2) =
a
h2
(N0 + 1)
2
N20
2 +
N0
2 +
1
24
As(I, I − 1) = a
h2
(N0 + I − 1)2
(N0 + I − 1)2 + 112
As(I, I) = − a
h2
(N0 + I − 1)2 + (N0 + 1)2
(N0 + I − 1) + 112
(3.15)
3-10 DIFFUSION IN THE LUNGS
Network of alveoli: Air in the lungs passes terminal bronchi, enters respira-
tory bronchi and consequently reaches the alveolar ducts and alveoli. This may
be interpreted as penetration of air through a porous material, i.e. lung tissue,
whose density increases with distance. Figure 3.3 illustrates the aforementioned
transport phenomenon. The material is assumed to be homogeneous, sponge-
like, whereas every alveolus has same properties. This assumption corresponds to
healthy lung tissue. Fractal properties have been applied to intergranullar materials
Figure 3.3: Conceptual view of air passing through a network of alveoli. In this picture,
the airflow has to reach every alveolus characterized by its own resistance, capacitance
and resulting lumped impedance.
for impedance models and sphere like geometry has been employed successfully
to proof convergence to a fractional order impedance model [51, 52]. The struc-
ture of such porous materials has been modelled with fractional calculus tools and
led to fractal dimensions between dimension 2 (surface) and 3 (volumetric). De-
pending on the density of the material, the values for fractal dimension changed
accordingly. In the context of lung pathology, changes in density occur in emphy-
sematous lungs. The fractional order impedance term values reflects these changes
and thus we speculate it might be of interest to study this aspect.
To illustrate the effect of changes in structure in tissue lungs, we will first dis-
cuss the nominal conditions of healthy lung tissue. The tools we employ are sim-
ilar as for one alveolus, equivalent ladder network models. Porous material is not
necessary permeable, therefore the pores we consider in our model are not linked
to each other, thus similar to alveolar sacs (dead-end). To enter these pores, the
airflow must counteract resistance with dissipative energy and must inflate/deflate
with an elastic capacitance which decreases the peak pressure for the same given
volume of air. The flow entering from the main stem we assume equally divided
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between the alveolar pores. Mandelbrot introduced the fractal character to porosity
because of self-similarity principle [42]. In this context, we may employ recurrent
ladder networks of parallel cells - each cell denoting an alveolus. Although Man-
delbrot introduced fractality in porous materials as randomly distributed (si ze and
location), due to the very compact structure of the lung ductuli we may consider
this parallel arrangement of cells as deterministic [40].
3.5 Patients
The study includes 43 COPD diagnosed patients (≥ 60 years) who came for peri-
odic evaluation of their lung function at Ghent University Hospital, Belgium. The
study group included: 18 subjects diagnosed with COPD-GOLD II; 15 subjects
diagnosed with COPD-GOLD III and 10 subjects diagnosed with COPD-GOLD
IV. Biometric and spirometric variables are listed in Table 3.1. Written informed
consent was obtained from all participants. This study and the consent procedure
was approved by the local ethical committee of Ghent University Hospital, Ethical
advice number B670201111936.
- COPD-GOLD II COPD-GOLD III COPD-GOLD IV
# Patients 18 15 10
Age (yrs) 71 ±9.4 77±5.7 68±3.5
Height (m) 1.62±0.07 1.7 ±0.087 1.66 ±0.035
Weight (kg) 70.4 ±10.59 78.5 ±10.66 75.4 ±13.64
Table 3.1: Biometric characteristics data for the subjects included in the study.
3.6 Results and discussion
Figure 3.4 depicts the impedance of an isolated alveolus with particular lung tissue
parameters. These parameters are given below, with units as given above [53–55]:
ρ = 350; c = 5000;λ = 0.05; (3.16)
It can be observed that the lumped impedance follows closely the explicit
impedance in a limited frequency range. This interval will depend on the param-
eters (3.16). Notice that changes with disease at alveolar level will affect the cell
elements (3.10), consequently will change the lumped impedance form and affect
the fractional order operator. Using the impedance of an alveolus, we can now
construct a network of alveoli. The origin of this impedance is not essential, as
long as its form has the term in fractional order to help us understand changes with
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Figure 3.4: Explicit impedance for individual alveolus simulated with healthy lung
parameters. Black thick line denotes the constant phase of the lumped impedance.
remodelling. Supposing that the flow is divided equally through the 5 alveolar sacs
as in Figure 3.5, then all impedances are equal and receive the air-flow in parallel.
This allows us to write the following admittance equation:
Y t = Y 1 + Y 2 + Y 3 + Y 4 + Y 5 (3.17)
with Y t = 1/Zt the total admittance and Yi the admittances of each alveoli, with
fractional order value n = 0.5. The total admittance will not change in phase,
only in amplitude, dependent on the amount of alveoli we take into calculus of
(3.17). In pathology, as explained before, the mechanical properties are altered as
a result of remodelling and lead to different fractional order values. Structure of
alveolar sacs also modifies, leading to various consistencies of network of alveoli,
as conceptually illustrated in Figure 3.2. So if we consider that we have the same
admittance form as in (3.17), but with the following elements:
Y 1 = Y 2 = 1/Zs
Y 3 = Y 4 = Y 5 = 1/Zs”
Zs(n = 0.5) and Zs” = Zs(n = 0.3)
(3.18)
The phase will be altered, varying between−0.3∗90o and−0.5∗90o. In COPD, we
also have the breaking of alveolar walls, creating larger spaces. This will induce a
different form of the admittance, as:
Y t = Y 1 + Y 2 + Y 3 +
1
Z4 + Z5
(3.19)
with the same n = 0.5 for i = 1, 2, 3 and n = 0.3 for i = 4, 5. This will also affect
the phase of the total admittance, but the limit values will be the same as those
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Figure 3.5: Schematic representation of an alveolar with 5 alveoli (left) and with broken
alveoli (right)
from (3.18). This mathematical framework provides the necessary support for the
multi-fractal dynamics exhibited by the lung parenchyma and much discussed in
literature under the resulting property of self-organized critically system Phase
dynamics and thus also phase transitions are direct result of remodelling effects as
a self-defence mechanism of the respiratory system towards disease.
The result for the impedance obtained with (3.17) is depicted in Figure 3.6 and
from (3.18) is depicted in Figure 3.7. It can be observed that the limit phase values
Figure 3.6: Impedance (Zt = 1/Y t) for all alveoli equal and n = 0.5 from (3.17).
are close to the expected values related from the fractional orders (−30o,−45o).
Finally, the result of the impedance with broken alveolar walls, as defined in (3.19)
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Figure 3.7: Impedance (Zt = 1/Y t) for mixed types of alveoli with impedances varying
fractional orders n = 0.3, n = 0.5, as given in (3.18).
is given in Figure 3.8. As a general remark about all these simulation results, the
magnitude values are unrealistically high. In reality, the very high alveolar surface
(224 alveolar sacs according to [40]) will reduce significantly the magnitude for a
single sac. Here we used generic values to illustrate the effects of various changes
occurring in such structures with pathology.
The simulation studies performed here suggest that the convergence of the frac-
tional order in model from equation (3.7) has a structural origin and variations are
directly related to structural changes. To our knowledge, such an analysis has not
yet been reported in specialised literature.
Assuming initial conditions zero for both air flow and pressure the Laplace
transform of (2.27) has the form in equation (2.30). This has similar form as the
last term in equation (3.7) and combining these relations lead to:
Q(s) =
τnsn
1 + τnsn
Q0
s
(3.20)
We have shown previously that such ladder networks converge to lumped form
[14, 28]:
Y (s) u (
s
ω
)n (3.21)
with n = r/(c + r) the fractional order term value dependent exclusively on the
ratio of the alveolar parameters. This relation defines the admittance of air-alveolar
interface. Changes in gas exchange area paired with disease evolution are related
to the mass of air which can be involved in the ventilation process. This implies
that the term in (3.20) has a time constant which is varying with the relative ratio
between gas exchange surface and air mass. The damping factor of such a system
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is independent on this term, but the natural frequency is inversely related to it via
the following relation ω = 1/τ .
The natural frequency will increase for same surface with lower air mass, as
expected in COPD patients. This is then always reflected by the balance of inertial
and capacitive properties in these patients which tend to be equal at frequencies
around 15 Hz and higher (in healthy, the resonant frequency is around 8Hz). In
terms of respiratory impedance, the resonant frequency is where the negative part
of the imaginary part of impedance (reactance) is equal to the positive part (i.e.
crosses the zero line) [14, 38]. The damping factor is a parameter reflecting the
Figure 3.8: Impedance (Zt = 1/Y t) for broken alveolar walls and mixed types of alveoli
with impedances varying fractional orders n = 0.3, n = 0.5, as given in (3.19).
capacity of the material for energy absorption. In the case of lung tissue damping
is mostly characterize by viscoelasticity. The increased lung elastance in COPD
due to more empty spaces in the alveolar structure will result in higher values of
tissue damping than in healthy patients. The model from (3.20) has been used
to mimic healthy and COPD patient by changing morphological parameter values
in (3.12)-(3.13). This impedance was then fitted to the model in (3.7) to extract
parameters from (3.8). The results are given in Figure 3.9 for tissue damping (Gr).
It can be observed that as damping is increased, in COPD it relaxes as the alveolar
walls are broken with COPD progress.
We do not have the possibility to measure non-invasively the impedance of
the alveolar network. Instead, we employ the forced oscillation technique, a well-
known lung function test broadly used to assess mechanical properties in lungs
[38]. Figures 3.10-left and 3.10-right depict the boxplots for the tissue damping
Gr and tissue hysteresivity ηr. Statistical analysis has been performed to identify
if a significant difference between the group exists. Anova tests have been applied
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Figure 3.9: Simulated tissue damping (Gr) in: 1 - healthy, 2 - COPD-GOLD II, 3 -
COPD-GOLD III and 4-COPD-GOLD IV (chronic obstructive pulmonary disease stage II,
III and IV).
to the data and it has been observed a significant difference in tissue damping
between the three groups: i.e. between: COPD-GOLD II and COPD-GOLD III;
COPD-GOLD II and COPD-GOLD IV; COPD-GOLD III and COPD-GOLD IV.
The p values identified for this case is lower than 0.01. Same analysis has been
performed also for tissue hysteresivity and a p value lower than 0.05 has been
identified.
The damping factor is a material parameter reflecting the capacity for energy
absorption. In materials similar to polymers, as lung tissue properties are very
much alike polymers, damping is mostly caused by viscoelasticity, i.e. the strain
response lagging behind the applied stresses [45,46]. The loss of lung parenchyma
(empty spaced lung), consisting of collagen and elastin, both of which are respon-
sible for characterizing lung elasticity, is the leading cause of increased elastance
in COPD. Damping will increase due to increased tissue density in places where
alveolar walls are not broken.
Since pathology of COPD involves significant variations between inspiratory
and expiratory air-flow, an increase in the hysteresivity coefficient ηr reflects in-
creased inhomogeneities and structural changes in the lungs. In emphysematous
lung, the caliber of small airways changes less than in the normal lung (defining
compliant properties) and peripheral airway resistance may increase with increas-
ing lung volume.
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Figure 3.10: Left: Tissue damping (Gr); Right Tissue hysteresivity (ηr) in: 1 -
COPD-GOLD II, 2 - COPD-GOLD III and 3 - COPD-GOLD IV (chronic obstructive
pulmonary disease stage II, III and IV).
Based on our proposed derivations to obtain (3.5) and (3.20), the model from
(3.7) has a strong theoretical basis linked to i) mechanical (resistance, elastance)
properties of lung parenchyma, ii) structural layout (recurrent properties) and iii)
tissue density (porous character). Alterations in these properties have an effect of
the overall impedance parameters and these can now be linked to changes in small
airways and alveolar levels. This in turn affects the degree of non-linearity in the
tissue dynamics. The T index has been calculated for each group and the results
obtained are presented in Figure 3.11-left.
Figure 3.11: Left: Boxplot for the non-linear distortions in COPD-GOLD II,
COPD-GOLD III and COPD-GOLD IV diagnosed groups. There is a significant
difference between groups. Right: Relation between T index and the heterogeneity factor
(ηn) is the evaluated COPD groups. ’o’ denote COPD-GOLD II, ’*’ denote COPD-GOLD
III and ’x’ denote COPD-GOLD IV.
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It can be noticed that there is a significant difference between the groups. From
the results obtained we may conclude that the T index increases as COPD disease
advances which is in line with prior rationale. Statistical analysis for the the T
index in the measured group has been performed and the results obtained are re-
ported in table 3.2.
Group Min Max Mean Std
COPD-GOLD II 0.7579 0.9840 0.8228 0.0488
COPD-GOLD III 0.8893 0.9568 0.9205 0.0229
COPD-GOLD IV 0.9836 1.0459 1.0019 0.0214
Table 3.2: Confidence intervals for the calculated T index in the measured groups. Std
denotes standard deviation.
In Figure 3.11-right the evolution of the hysteresivity factor as a function of
the T index is presented. The results obtained indicate that as COPD continues
to deteriorate the alveolar walls the heterogeneity of the lungs will decrease as
larger spaces occurs. However, the effects from changes at macromolecular level
contribute to increased non-linear dynamics. The results indicate there exist a
correlation between the T index and the heterogeneity factor (i.e. T increases ad
the COPD disease advances). The added value of the T index is that it can be
extracted directly from the measured signals without the necessity of (3.7).
3.7 Summary
In this chapter the importance of gas diffusion in patients with COPD disease has
been investigated. A model of diffusion for COPD diagnosis does not exist and in
this thesis a first step towards the development of such model has been taken. The
proposed model has been simulated by means of numerical examples. The choice
of number of alveoli was not based on any design specification but has been se-
lected as a suitable number (either too low either too high) for the purpose of the
study. The alveolar structure and morphology is drastically affected and thus plays
an important role in determining the viscoelastic properties of lung parenchyma.
Loss of alveolar surface area and dysfunction of the alveolar membrane as in em-
physema lead to a decrease diffusion factor. Measurement of the diffusion factor
can be of importance in (early) detection of COPD disease. Several methods to
determine the diffusion factor have been investigated. Each method has its own
advantages and limitation. The single breath method became the most generally
accepted method.
In this chapter the available tools emerging from fractional calculus to model
changes in COPD and to understand their effect on model parameters values have
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been presented. The theoretical basis helps in understanding the interplay between
all these structural and dynamical changes. The results obtained indicate that there
is a direct relation between the T index and the heterogeneity in COPD lungs. A
limitation of this study is that effects of decrease in vascularisation associated with
broken alveolar walls are not investigated. This implies an augmentation of the
model with complex mathematical description of diffusion phenomena. However,
these are pertinent next steps in further developing the mathematical of fundaments
respiratory mechanics. The obtained results are promising and is definitely worth
to further investigate this hypothesis.

4
Towards a Pain Nociceptor Model
This chapter makes the soft transition from modeling diffusion in the lungs (Chap-
ter 3) to modeling drug diffusion (Chapter 5). However, before investigating the
use of diffusion models to characterize drug effect and uptake its necessity is ad-
dressed. Therefore, in this chapter the existing tools/methods/techniques and de-
vices available to assess pain are presented. The contribution of this chapter to the
remaining of the thesis is to indicate the gaps towards an objective pain assessment.
The publications related to this chapter are:
1. D. Copot, C.M. Ionescu, Objective Pain Assessement: How far are we?, E
Cronicon Anesthesia Journal, Special Issue on Critical Care and Importance
of Anaesthesia for Pain Relief, SI 01, 11-14, 2018,
2. D. Copot, C. Ionescu, Pain monitoring tools: a systematic review, Journal
of Clinical Monitoring and Computing, 2018, submitted.
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4.1 Introduction
Despite the importance of pain in medicine and biology, it is astonishing to dis-
cover that the word ”pain” has been never defined satisfactorily.
• First definition states that ”pain is that sensory experience evoked by stimuli
that injure or threaten to destroy tissue” [56].
• Second definition describe pain as an abstract concept which refers to 1) a
personal, private sensation of hurt; 2) a harmful stimulus which destroy the
tissues; 3) a pattern of responses which operate to protect the organism from
harm” [57].
• Third definition is much better, but still falls short from being acceptable
to all. Merskey et al. define pain as an unpleasant sensory and emotional
experience associated with actual or potential tissue damage, or described
in terms of such damage [58].
Pain is a highly personal experience and the patient is thus the best infor-
mant [59–62]. Pain is a multidimensional phenomenon that includes physiologic,
sensory, affective, cognitive, behavioral, and sociocultural aspects. Several factors
such as: age, race, gender etc. seem to modify patients’ pain perception and re-
porting [63–66]. Despite modern techniques, pain remains a subjective experience
and health care professionals have to rely on patients ratings [67]. Methods to ac-
curately characterize patients pain level during unconsciousness are needed. For
the case of intensive care unit there is no objective tool to evaluate the level of pain
that the patient is experiencing.
Therefore, optimal pain assessment in intensive care units (ICU) is essential
since it has been reported that 35% to 55% of nurses underrate patients pain
[68, 69]. Moreover, in [70] has been reported that 64% of the patients did not
receive any medications before or during painful procedures. In the SUPPORT
(Study to Understand Prognoses and Preferences for Outcomes and Risks of Treat-
ment) report [62], nearly 50% of patients reported pain, 15% reported moderately
or extremely severe pain that occurred at least half of the time of the procedure,
and nearly 15% were dissatisfied with their pain control. Inaccurate pain assess-
ment and the resulting inadequate treatment of pain in critically ill adults can have
significant physiologic consequences [71].
Hitherto, patient self-report is the best indicator of pain, e.g. using the nu-
meric pain rating scale ranging from 0 to 10. However, many critically ill patients
are unable to communicate effectively because of cognitive impairment, sedation,
paralysis, or mechanical ventilation. Identification of the optimal pain scale in
such patients is ongoing, and no single tool is universally accepted for use in the
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non-communicative (anesthetized) patient [72, 73]. When a patient cannot ex-
press himself, observable indicators - both physiologic and behavioral - have been
treated as pain-related indicators to evaluate pain level [74]. A more detailed de-
scription of the available tools is presented is given in section 2.
Therefore, there is a clear evidence that no accurate physiologic or clinical
signs that can be used to objectively measure pain exists. Reliance on healthcare
worker assessment of patient pain results in underestimation of the intensity of
pain. According to the National Institutes for Health (NIH), patient self- reporting
is the ”most reliable indicator of the existence and intensity of pain” [75] Subjec-
tive pain measures that may need to be quantified include intensity, time course,
quality, impact, and personal meaning. The ideal tool in the assessment of pain
should include the identification of the presence of pain, as well as the progress
of pain with time or treatment [76]. Also, this ideal tool should be applicable to
any individual, regardless of psychologic, emotional, or cultural background. To
that end, unidimensional pain scales have been developed. Because of their ease
of use, these scales have become popular tools used to quantify pain relief and
pain intensity. The most frequently used tools to assess acute pain are the numeric
rating scale (NRS) and the visual analogue scale (VAS).
Although popular for study purposes, unidimensional pain scales have short-
comings. They were initially developed for use in experimental pain trials in which
pain was limited and controlled. Clinical pain is different in the sense that it may
become persistent, unbearable, and beyond the individual’s control. It is also often
associated with a strong emotional component not observed in the experimental
setting. Pain scales tend to focus only on pain intensity, with increased risk of
oversimplification of this complex experience. Furthermore, actual measurements
are relative only to the individual being assessed. Identical stimuli applied to dif-
ferent individuals can yield to significantly different scores. Thus the numbers are
simply estimates of the perception of the pain, based on past personal experience.
Quantification of the experience requires the individual to abstract and quantify the
sensation. The use of unidimensional pain scales is more appropriate in the setting
of acute pain (caused by surgery, broken bone, burns, etc.) than chronic pain (e.g.
headache, cancer pain, low back pain, etc.). Chronic pain is usually associated
with other events such as degree of support and depression. The assessment of
chronic pain often requires more complex evaluation tools.
Hence, pain is an subjective experience, and hitherto no objective tools exists
to measure it. When possible, the existence and intensity of pain are measured
by the patients self-report (i.e. conscious patients). Unfortunately, some patients
cannot provide a self-report of pain either verbally, in writing, or by other means,
such as finger span [77] or blinking their eyes to answer yes or no questions [78].
Effective management of analgesia in the ICU units requires an assessment of
the needs of the patient, subjective and/or objective measurement of the key vari-
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ables (such as pain, agitation, and level of consciousness), and titration of therapy
to achieve specific targets [72, 79, 80]. It is important to admit that patient needs
can differ depending on clinical circumstances, and that for any given patient ther-
apeutic targets are likely to change over time. Thus, achieving patient comfort and
ensuring patient safety, including avoidance of over- and under-dosage, relies on
accurately measuring pain, agitation, sedation, and other related variables. This
should be evaluated with validated tools that are easy to use, precise, accurate, and
sufficiently robust to include a wide range of behaviors. From the point view of
analgesia there is still a missing puzzle piece with respect to the existence of a ob-
jective pain measurement tool for general anesthesia. In this chapter a systematic
review describing instruments/tools developed for pain measurement in conscious
and unconscious patients will be reported.
4.2 Pain measurement during consciousness
Wide variation in the experience of chronic and neuropathic pain has led to the
development of a broad range of pain measurement instruments. In general, pain
measures can be classified into four groups: i) measures of pain intensity; ii) pain
characteristics; iii) pain interference; iv) pain relief or global change. In addition,
there are multiquestion measures to differentiate between types of pain (chronic
and acute).
A first class of tools used for pain measurement include: NRSs, VASs, ver-
bal rating scales (VRSs), percentage scale and graphical scales. In research and
clinical settings, the above mentioned tools are being predominantly used to eval-
uate pain intensity. All tools produce good results as long as they are properly
administered [83, 84] and all are highly correlated. These pain scales are reliable
for multiple measurements within a single individual, but there is high variability
among individuals with chronic pain. This variability makes it difficult to interpret
the clinical importance of single pain measurements, but the change over time is a
reliable and valid outcome for clinical trials. The improvement of pain assessment
(expressed as a percent change to control for different baseline pain intensities) is
highly correlated with his or her overall condition [86, 87].
Verbal rating scales typically consist of a series of verbal pain descriptors or-
dered from least to most intense (e.g., no pain, mild, moderate, or severe) [88].
Patients read the list and choose the word that best describes the intensity of their
pain. A score of 0 is assigned to the descriptor with the lowest rank, a score of 1
is assigned to the descriptor with the next lowest rank, and so on. Numeric rating
scales typically consist of a series of numbers ranging from 0 to 10 or 0 to 100 with
endpoints intended to represent the extremes of the possible pain experience and
labeled no pain and worst possible pain respectively. Patients choose the number
that best corresponds to the intensity of their pain. Although VRSs and NRSs are
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simple to administer and have demonstrated reliability and validity, the advantages
associated with VASs and is the measurement instrument of choice when a unidi-
mensional measurement of pain is required; however, this may not be true when
assessing chronic pain in elderly patients. One study indicated that elderly patients
make fewer errors on VRSs than on VASs.
A second class of pain measurement tools is based on questionnaire format.
These tools are defined on a set of questions used to interrogate the patients about
their pain. The clarity and specificity of the questions used will affect the reliabil-
ity of the answers and the degree to which the questions relate to the process being
studied-which is, their validity. Questionnaires are developed for one of the fol-
lowing purposes: to identify people with a specific condition within a population
(discriminative), or to evaluate the change in a condition over time (evaluative).
Although some scales aim to do both, the features that distinguish a specific con-
dition are often not the best ones to follow over time. The format of each question
contains several common elements, such as the condition being measured, the time
frame, and modifiers of each, as needed. In Figure 4.1 an overview of the methods
used for pain quantification in conscious patients is given.
4.3 Pain measurement during unconsciousness (e.g.
general anesthesia)
Whereas routine pain assessment procedures can be used with ICU patients who
are verbal, a substantial number of ICU patients may not be able to provide a
self-report of the presence or intensity of their pain. The assessment of pain in
these nonverbal critically ill patients poses numerous challenges. Research on the
measurement of pain in critically ill adults who cannot self-report (referred to as
nonverbal ICU patients) has emerged only within the past 2 decades. However,
no measure of pain in nonverbal ICU patients is accepted as the gold standard. In
this chapter six objective pain measures for use with nonverbal ICU patients and
evaluation of the strengths and weaknesses of these measures will be discussed.
Objective pain measures are provided by observational instruments that can
be categorized as either unidimensional or multidimensional. A unidimensional
objective measure (eg, behavioral scale) may use a single domain (eg, facial ex-
pression) or several domains (eg, facial expression, body movements, sound, etc.)
to evaluate a persons responses to pain. A multidimensional objective measure
evaluates 2 or more pain dimensions (eg, behaviors, physiologic responses) and
has several domains within each dimension. In the absence of self-report, unidi-
mensional measures with multiple domains or multidimensional measures are the
preferred tools to evaluate acute pain in nonverbal ICU patients [89].
The following unidimensional tools have been developed: Behavioral Pain
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Figure 4.1: Pain measurement tools used for conscious patients.
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Rating Scale (BPRS), Behavioral Pain Scale (BPS), Pain Behavior Assessment
Tool (PBAT) and Critical-Care Pain Observational Tool (CPOT).
The BPRS is a unidimensional objective measure that assesses 4 behavioral
domains: restlessness, tense muscles, frowning or grimacing, and patient sounds.
Each domain contains 3 descriptors that indicate a progressive increase in pain
severity and are scored on a scale that ranges from 0 (normal behaviors) to 3 (ex-
treme pain behaviors). The total BPRS score (the sum of all domains scores)
ranges from 0 (no pain) to 12 (most pain). Although the BPRS appears to pos-
sess satisfactory internal consistency, generalization of the BPRS findings [90–92]
to nonverbal ICU patients is limited because it was tested in small homogeneous
samples of post-anesthesia care unit (PACU) patients. In fact, patients with major
complications and neurological problems were excluded from the studies. More-
over, the BPRS requires a patient to vocalize and to show discernible movements,
which is limiting its use in a substantial percentage of nonverbal ICU patients who
may be intubated, have an altered level of consciousness (LOC), unconscious pa-
tients or who have received neuromuscular blocking agents.
The BPS evaluates 3 behavioral domains (ie, facial expression, movements of
upper limbs, compliance with ventilation). Each domain contains 4 descriptors
that are rated on a 1 to 4 scale and the total BPS score can range from 3 (no pain)
to 12 (most pain). Findings from 3 studies [90, 91, 93] suggest that the BPS is a
valid and reliable measure for use in nonverbal ICU patients. However, attention
to a number of factors would improve its clinical utility. First, the range of scores
on the BPS (ie, 3 = no pain to 12 = most pain) should be revised so that a score
of 0 reflects no pain behavior. Second, on the BPS, the lack of body movement
equates with a pain-free state which is not most of the time the case for the ICU
ward. Moreover, during general anesthesia none of this tools can be used to
evaluate pain during surgery for computerized closed loop drug titration.
The PBAT unidimensional assessment tool was developed for a large-scale de-
scriptive study of patients pain perceptions and behaviors associated with common
hospital procedures in acute and critical care settings [94]. This tool consists of
3 behavioral domains with several descriptors within each domain (ie, facial ex-
pressions = 10 descriptors; body movement = 15 descriptors; verbal responses =
7 descriptors). The PBAT contains a number of features that enhances its clinical
utility. The assessment procedure is simple (ie, mark the presence of a behavior)
and not subject to interpretation. This approach contrasts with conventional ob-
jective pain measures that assign scores at the item level and use a sum score to
indicate patients level of pain. To increase its applicability for use in nonverbal
ICU patients, the tool requires modifications to the verbal response domain and
the body movement domain because certain descriptors (eg, moaning, guarding,
massaging) are not applicable in nonverbal patients with a decreased LOC. Addi-
tional evaluation is needed to confirm responsiveness of the PBAT to other sources
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of acute pain, as well as to the administration of analgesics.
The CPOT is a unidimensional measure designed for use with intubated and
nonintubated ICU patients. It evaluates four behavioral domains (ie, facial expres-
sions, movements, muscle tension, ventilator compliance). Each CPOT domain is
scored from 0 to 2, and the total score ranges from 0 (no pain) to 8 (most pain) [93].
However, the responsiveness of CPOT behaviors to painful stimuli in deeply se-
dated patients remains to be determined.
The following multidimensional tools have been developed: Pain Assessment
and Intervention Notation (PAIN) Algorithm and Nonverbal Pain Scale (NVPS).
The PAIN Algorithm is a systematic pain assessment and management tool
developed for research testing with critical care nurses. This tool consists of
3 parts: pain assessment; assessment of patients ability to tolerate opioids; and
guidelines for analgesic treatment decisions and documentation. The pain assess-
ment prompts nurses to observe the patient for the presence or absence of 6 be-
havioral domains (ie, facial expression, movement, posture, vocal sounds, pallor,
perspiration) and 3 physiologic indicators (ie, heart rate (HR), blood pressure (BP),
respiration). Then, the tool prompts nurses, based on their appraisal of these di-
mensions of pain, to rate the severity of the patients pain on a 0 (no pain) to 10
(most pain). The PAIN Algorithm may be a useful tool to standardize pain as-
sessment and management in the ICU. However, the length of the tool limits its
clinical utility [93]. Another limitation of this tool is that it does not standardize
the measurements of behavioral and physiologic responses.
The NVPS includes 3 behavioral domains (ie, facial expression, body move-
ment, guarding). Additionally, 4 physiologic domains were added based on a re-
view of literature and grouped into 2 categories: Changes in vital sign over 4
hours and changes in skin color, warmth, and pupil dilation. Each NVPS domain
is scored from 0 to 2 and the total score can range from 0 (no pain) to 10 (most
pain). The NVPS has limited content validity and reliability as a pain measure for
nonverbal ICU patients. First, certain NVPS behavioral descriptors such as smile
or lying in normal position cannot be equated with a nonpainful state. Moreover,
measurement of the physiologic indicators (eg, pupil dilation, perspiration) was
not defined or standardized. In addition, the authors did not describe the rationale
for their selection of vital sign parameters for pain (eg, respiratory rate increased
by >10 breaths/min over 4 hours, SBP increased by >20 mm Hg over 4 hours).
Despite advances in pain research and management, the measurement of
pain in nonverbal ICU patients remains an immense challenge for critical care
clinicians. The dilemma of adequate versus inadequate pain management in these
high-risk patients is largely attributed to the lack of vigorously tested valid and
reliable pain measures. This critical review demonstrates that although 2 objec-
tive pain measures (ie, BPS, CPOT) showed validity and reliability, they have not
received rigorous evaluation to consider them as a robust pain measure for use in
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Figure 4.2: Pain measurement tools used to measure level of pain in non-communicative
patients (i.e. unconsciousness).
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nonverbal ICU patients. Although the discussed tools are mentioned as an objec-
tive way to measure pain, there is much room for improvement due to the fact
that these tools are based on several domains and they are still depending on the
experience of the nurse. Therefore, it cannot be claimed that with these tools the
actual pain the patient is experiencing is being also the measured pain. In Figure
4.2 an overview of the available tools for pain assessment during unconsciousness
is presented.
In conclusion, pain assessment is largely depended on the ability to rate per-
sonal subjective pain. Moreover, pain scales can be difficult to use during medical
procedures. Several techniques have been developed for conscious and uncon-
scious patients. For the first category (i.e. consciousness) most optimal tools for
pain measurement are the VAS and NRS, but also the other techniques presented
in this review are being used to evaluate pain level. For the second category (i.e.
unconsciousness) several devices/tools have been developed in order to evaluate
pain level. Even if effort has been made to develop an objective and individualized
pain measurement device for unconscious/non-communicative patients there is no
such tool is used in clinical practice. The first steps towards the development of
such an objective pain assessment tool have been undertaken in this thesis.
4.4 Commercial Devices
In the last fifteen years the research effort on developing a device for objective
measurement of pain has increased. As a result, nowadays there are three medical
devices available on the market for pain assessment. Each of them is designed for
a certain category of patients. A description of the available devices along with
their advantages and disadvantages is given hereafter.
Med-Storm Pain Monitor is designed for infants, children and adults, with
more focus on infants and children. This device is based on the measurement of
skin conductance (SC) to monitor nociceptive stimulation, awareness and pain.
Various methods of pain assessment in infants have been trialled in the search for
objective, specific, physiologic measures of responses to pain. SC measured in the
palm of the hand or on the plantar area of the foot may be one such measure. SC in
these sites reflects the emotional sweating due to sympathetic nerve activity. The
skin conductance response (SCR), which results from filling and reabsorption of
sweat in the sweat glands, has previously been suggested to be the most sensitive
SC parameter of sympathetic nerve activity in response to painful stimulation [95].
SC activity is caused by the release of sweat from the sweat glands upon activa-
tion of the sympathetic nervous system which in turn acts on muscarinic receptors
in the sweat glands [96]. On cessation of this gland stimulation, fluid is reabsorbed
from the ducts and the conductance decreases. This can be recorded as a ‘wave’
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or a ‘fluctuation’ in electrodermal measurements [97], namely a SCR. SCR have
a relatively steep onset and a flat recovery; that is, SCR rise time is shorter than
recovery time. The steep onset represents the release of sweat from the secretory
duct and the flat recovery is caused by the slower reabsorption of sweat within the
duct.
In [95] the skin conductance variability between hospitalized infants at rest
has been reported. The aim of the study was to investigate the hypothesis whether
or not the SCR can be used as a parameter of stress [98, 99]. The outcome of
the study indicated that the variability was higher for intra-patient variability than
for inter-patient variability. The intra-patient variability was almost three times
larger than inter-patient variability, i.e. 0.93 vs 0.27. The authors have reported
that the observed variation in the heart rate implies problems with using heart
rate as a physiological indicator for pain. They also indicated that although heart
rate and oxygen saturation are considered sensitive indicators of pain, they lack of
specificity. In this pilot study the authors intended to establish a baseline for SCR
in hospitalized infants at rest. As the number of participants was small, further
studies are required to determine the validity and reliability of the SC measurement
as an added component to routine clinical pain monitoring device for critically ill
infants.
The aim of the research performed in [98] was to investigate if the spontaneous
SC activity can be used to measure the stress response to heel stick in premature
infants. In this study twenty premature infants have been monitored. The outcome
of this study indicates that the measurement of spontaneous SC activity showed
stress responses to heel stick from at least 29 weeks age in healthy premature
infants. The authors claim that the number and amplitude of the waves of spon-
taneous SC activity mirrors the response to sympathetic nervous system to the
emotional state. From this study they also concluded that SC activity variables
may be a useful tool for surveying stress responses to pain stimuli in premature
infants. In a later a review on the capability of the SC to monitor pain and com-
parison to other physiological pain assessment tools in children and neonates has
been reported [100]. In the intensive care units and at neonatal units the SCRs/sec
showed a high sensitivity to monitor pain, but again, low specificity.
In [101] a comparison between the Wong-Baker Faces Scale (gold standard
in clinical practice) versus SC has been investigated. In this study 150 children
have been evaluated during routine care. The outcome of this study indicated that
the self-reported pain score was significantly lower that the SC score. One of the
limitations of the study is the lack of previous comparison between SC and Wong-
Baker faces scale (see Figure 4.3). Another limitation is the difficulty to convert
the SC data in a numerical scale that could be compared to Wong-Baker faces
scale.
1http://wongbakerfaces.org/
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Figure 4.3: The Wong-Baker Faces Scale 1
Med-Storm Pain MonitorTM system consists of a software that operates under
Windows R© together with a measuring unit and disposable sensors. The software
has three different modes for different patient populations. In the anaesthesia mode
it registers peaks/sec and area under curve. In the post-operative mode peaks/sec
are recorded. In the infant mode peaks/sec are registered. When the research mode
is selected, values of ‘area huge peaks’, ‘area small peaks’, ‘peaks per second’,
‘average peak’, ‘average rise time’ and ‘signal quality’ are displayed. When off-
line, the software can be used to analyse recorded data. Recorded data can be
exported to Microsoft Excel R© . The electrodes are placed on the palm of the hand
(adults) or around the foot (neonates). In Figure 4.4-left the measurement device is
depicted and in Figure 4.4-right the variation of in skin conductance during three
painful stimuli is presented.
Figure 4.4: Med-Storm Pain Monitor 2
2http://www.med-storm.com/
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AlgiScan is a pain monitoring device based on pupillary reflex dilatation (PRD)
and it has been developed for patient during anaesthesia In the last 20 years PRD
has been studies as a potential marker for response to noxious stimulation in
volunteers and surgical patients. Several studies have shown that in response to
an incision or tetanic electrical stimulation of the skin, PRD monitoring permits
the detection of a dramatic increase in pupil size, even during general anaesthe-
sia [102–104]. In [103] a pilot study has been conducted in order to test the hy-
pothesis whether or not the PRD can be used to assess noxious stimulation and
analgesic effect in children undergoing anaesthesia. In [105] the performance of
pupillometry to detect differences in PRD response to a standardised noxious stim-
ulus during continuous infusion of Remifentanil has been investigated. The out-
come of this study was a proof of concept that the method can perceive the effects
of peripheral nerve block in patient receiving infusion of Remifentanil.
In [106] evaluation of the device in sedated patients has been investigated.
In this study a comparison of the pupil size with heart rate, blood pressure and
bispectral index has been performed. This study suggests that certain physiological
reactions and pupil size changes may be potentially useful nociceptive indicators in
ICU settings. However, this preliminary study does not suffice and further research
is required in order to determine the clinical parameters of physiologic response
change and evaluate the effects of opioids and sedatives on these responses.
In [107] a analysis on the objective assessment of the postoperative analgesia
using the PRD method has been investigated. In this observational study pain in-
tensity has been assessed by means of a VRS. Before and after drug administration
to the patient, PRD has been measured. It has been noticed that the PRD index in
the immediate postoperative period is significantly correlated with the VRS.
Figure 4.5: AlgiScan measurement device3
In Figure 4.5 the AlgiScan device is depicted along with a pain pupillary index
(PPI) test. In this case the pupillary response to electrical stimulation indicates an
insufficient level of analgesia for an surgical incision (i.e. PPI score 6/10).
3http://www.equip.nl/en/specialization/anesthesia/analgesia-monitor.html
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MEDASENSE is another device based on a multi-parametric index for as-
sessment of the presence and severity of pain. This technology combines the non-
invasive probe incorporating 4 sensors (photoplethysmograph, galvanic skin re-
sponse, temperature, and accelerometer). The finger probe continuously acquires
physiological signals through four sensors. Several pain-related physiological pa-
rameters and derivatives are extracted and computed (heart rate, heart rate vari-
ability, pulse wave amplitude, skin conductance level, number of skin conduc-
tance fluctuations, temperature and more). Advanced machine learning algorithms
identify the pain-related pattern and reflect the information on a scale where 0
represents no pain and 100 represents extreme pain - the nociception level (NOL)
Index. NOL provides superior indication of the presence and severity of pain ver-
sus individual parameters (such as changes in heart rate and blood pressure). A
figure of the device is given in Figure 4.6.
Figure 4.6: MEDASENSE measurement device4
Several studies have been published on the use and potential of this technol-
ogy. In [108] a study on the development and validation of this method has been
investigated. In this paper the NOL for patients undergoing anaesthesia has been
reported. This study suggest a new index for non-invasive assessment of patient
level of nociception during anaesthesia, based only on physiological parameters.
In [109] the ability of the NOL to detect noxious stimuli during anaesthesia has
been investigated. A comparison with heart rate and mean arterial pressure was
performed. The results indicate that during nonnoxious event none of the param-
eters have changed. When incision took place an increase of the monitored pa-
rameters has been noticed. The outcome of this papers indicates that in contrast
with heart rate and mean arterial pressure, the NOL was not affected by hemody-
namic effects of Remifentanil. Another study [110] has investigated the abilities
of NOL index and other measures of nociception to discriminate between noxious
and nonnoxious stimuli, to progressively respond to graded stimuli and to respond
to opioid administration. These studies suggest that the NOL index is a potential
index to distinguish nonnoxious and graded noxious stimuli as well as the response
to opioids.
4https://www.medasense.com/
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The devices presented in this chapter have been evaluated mostly on sedated
patients. Therefore, there is still much room for improvement. Although, clini-
cally needed and theoretically promising, currently there is not enough evidence
(i.e. clinical trials) to support the widespread use of any physiological sensors as
”objective” measures of pain. Another drawback is that none of these devices are
based on mathematical interpretations/descriptions/models of pain.
4.5 Summary
In this chapter a detailed overview of the existing methods and devices available
for pain assessment has been given. From here, one may conclude that the exist-
ing methods are subjective (i.e. based on patient feedback). With respects to the
available devices two main conclusions can be drawn: 1) these devices are not yet
employed in clinical settings as standard tools for pain assessment. This is due
to the lack of large clinical trials but also, because each of them is for a certain
class of patients. 2) none of them is based on a mathematically-physiologically
based model. The challenges identified in this chapter are further exploited in the
remaining of this thesis.

5
Pharmacokinetics-Pharmacodynamics
Models of Drug Uptake and Drug
Effect
In this chapter drug diffusion in the human body by means of compartmental mod-
els is presented. Fractional calculus tools are employed to characterize the profiles
of drug concentration in each compartment.
The main publications where this work has been presented are:
• D. Copot, R. Magin, R. De Keyser, C. Ionescu, Data-driven modelling of
drug tissue trapping using anomalous kinetics, Chaos, Solitons and Fractals,
102, 441-446, 2017.
• D. Copot, A. Chevalier, C.M. Ionescu, R. De Keyser. A Two-Compartment
Fractional Derivative Model for Propofol Diffusion in Anesthesia, IEEE
Multi-Conference on Systems and Control, Hyderabad, India, 28-30 Au-
gust, 264-269, 2013.
• C.M. Ionescu, D. Copot, On the use of fractional order PK-PD models,
European Workshop on Advanced Control and Diagnosis, Lille, France, 17-
18 July, 1-12, 2017.
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5.1 Introduction
Selecting appropriate models is a crucial step in capturing complex biological and
physiological phenomena. Any choice of a model structure implies a simplified
view of the interaction among the various elements that may characterise a dy-
namical system. In pharmacokinetics, a popular choice is that of compartmental
models, due to their implicit simplicity and ease of understanding in relation to the
mass balance equations and assumptions for uniform distribution, homogeneous
transient times and immediate response to drug bolus administration [111]. Nu-
merous works and decades of research have tailored their applicability for optimal
drug delivery assist devices in several domains of medical applications, e.g. di-
abetes [112], cancer [113, 114], anaesthesia [115], immunodeficiency [116] and
hormonal treatment [117].
Providing a best fit to data from observed drug concentration profiles implies
the existence of some error tolerance intervals. Emerging tools from fractional cal-
culus have proven useful to improve to a great degree the accuracy of dynamical
models with respect to classical integer order modelling theory [118, 119]. The
acceptance of these tools within the engineering community has led perhaps to a
significant step forward in terms of data driven modelling and numerical simula-
tion [120, 121]. However, their acceptance in clinical practice may require further
tailoring for a better characterization of patient variability [122–124].
Compartmental models are a traditional tool for modelling drug pharmacoki-
netics (PK) in applications of general anaesthesia. The depth of anaesthesia regu-
latory problem consists of optimal calculation via such patient PK models of the
amount of drug necessary to achieve a desired sedation level, irrespective of arte-
facts and disturbances [125]. Attempts to fractionalise PK compartmental models
for anaesthesia have been done with simulated data. A net advantage however has
not been shown, since secondary effects due to drug trapping were not accounted
for at that time [126, 127].
Pharmacokinetic model gives information about the concentration profile of
a drug as a function of time, in the body fluid (i.e. blood) as a result of a dose
administration (e.g. bolus injection). Compartmental models seems to be widely
used, while they provide a continuous description of the concentration that can
serve as a input function for the pharmacodynamic part. In general, the pathway
of a drug through the body can be separated into three distinct phases: uptake,
distribution, and elimination.
Uptake: Different routes of administration produce variability in the rate of
drug uptake and amount of drug delivered effectively to the body. Intravenous
administration of a drug results in the entire dose entering the plasma immediately,
although it must pass initially through the pulmonary circulation and some drugs
(e.g. fentanyl) have significant take-up by the lungs [128].
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Distribution: After intravenous administration of a drug, the peak blood con-
centration is determined by the dose, the rate of administration, and the cardiac
output. With a high cardiac output, the effective volume of blood in which the
drug is initially diluted is larger, leading to a lower peak concentration. A high
cardiac output transports the drug fast to the vessel-rich tissues (including brain),
and for highly lipid-soluble drugs, fast equilibration takes place, leading to a fast
onset of action. Therefore, a low cardiac output leads to a higher initial peak
concentration, because the drug is mixed with a smaller volume of blood during
injection, though it will take longer to reach its target site [128]. All the aspects
mentioned above explains why a smaller dose of induction agent is required in an
elderly or shocked patient but may have a slower onset of action, while a young
patient may require a much larger dose, but they will start to feel the effects more
quickly.
Elimination: Full recovery depends on the removal of the drug from the body.
Such elimination may result from excretion, metabolism, or a combination of of
the two drugs. Large molecular weight drugs are often excreted in the bile, but
most drugs are renally excreted. In order for the kidneys to handle lipid-soluble
drugs, they need to be metabolized into a polar, water-soluble form. Most of this
metabolism occurs in the liver and can be divided into two phases reactions. Phase
one is the reaction which consist in oxidation, reduction, and hydrolysis, while
in the second phase reaction consist in conjugating the resulting metabolites with
sulphate, glucuronide, or other groups. For most drugs, elimination occurs in an
exponentially declining manner, the rate of elimination being proportional to the
plasma concentration, as the downstream end of the gradient remains at zero [128].
This system (i.e. the amount of drug being removed is a constant fraction in unit
time rather than a constant amount) is known as first-order kinetics. The phar-
macokinetic model represented in Figure 5.1 is represented traditionally by the
following equations (5.1)-(5.4).
From the point-of-view of regulating anesthesia, mathematical modeling of
drug diffusion can be very useful to better understand the mechanism of drug de-
livery systems. Therefore, the description of drug transport into the human body
can be highly beneficial [18–20] from two points-of-view: (i) allows one to under-
stand the insight of the mechanism and (ii) allows one to do quantitative predic-
tion of the effects of formulation and processing parameters on the resulting drug
release kinetics. The major challenge in the development or optimization of auto-
mated drug delivery systems is to achieve optimal drug concentration at the site of
action. In order to have the optimal concentration-time-profile at the site of action
the release of the drug must be controlled as accurately as possible.
Pharmacokinetic/pharmacodynamics (PK/PD) models represents an important
step in the process of drug development and this modeling tool also brought a
significant contribution to anesthesia. PK/PD models are a set of mathematical
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equations used to predict the drug effect in time. PK models describe what the
body does to the drug in terms of ADME parameters (i.e. Absorption, Distribu-
tion, Metabolism and Elimination). PK modeling for analgesic, opioid and mus-
cle relaxants drugs has been studied by several authors. In its classical version,
compartmental analysis is based on mathematical models, typically in the form
of systems of ordinary differential equations (see equations (5.1)-(5.4)) that are
widely used to characterize the uptake, distribution and elimination of a drug into
the body.
q˙1(t) = K21q2(t) +K31q3(t)−K12q1(t)−K13q1(t)−K10q1(t)−
K1eq1(t) + U(t)
(5.1)
q˙2(t) = K12q1(t)−K21q2(t)−K20q2(t) (5.2)
q˙3(t) = K13q1(t)−K31q3(t)−K30q3(t) (5.3)
q˙e(t) = K1eq1(t)−K0eqe(t) (5.4)
where: q1, q2 and q3 [mg] denotes the amount of drug in the three compartments
and V1, V2 and V3 represents the volume in the three compartments. The drug
concentration in the blood is expressed by q1/V1, respectively q2/V2 and q3/V3
for compartment 2 and 3. The peripheral compartments 2 (muscle) and 3 (fat)
represents the drug exchange of the blood with well and poorly diffused body
tissues. The parameters Kij denote the drug transfer frequency from the i− th to
the j − th compartment and U(t) [mg/s] is the infusion rate of the drug into the
first compartment. The parameters Kij of the PK models depend on age, weight,
height and gender and can be calculated for Propofol as follows: V3 represents the
volume of fat and is calculated using equation (5.5), while V1 and V2 are known
(V1=4.27 (L) and V3=2.38 (L)).
V2 = 18.9− 0.391(age− 53) (5.5)
Clearance is calculated as follows:
Cl1 = 1.89 + 0.456(weight− 77)− 0.0681(lbm− 59) + 0.0264(height− 177)
(5.6)
Cl2 = 1.29 + 0.024(age− 53) (5.7)
and Cl3 = 0.836 (l/min). where Cl1 is the rate at which the drug is cleared from
the body, and Cl2 and Cl3 are the rates at which the drug is removed from the
central compartment to the other two compartments by distribution.
The lean body mass (lbm) for men and women has the following expressions:
bmman = 1.1 ∗ weight− 128weight
2
height2
lbmwomen = 1.07 ∗ weight− 148weight
2
height2
(5.8)
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A schematic representation of a three compartmental model is presented in
Figure 5.1.
Figure 5.1: General compartmental model of the patient, where PK denotes the
pharmacokinetic model and PD denotes the pharmacodynamic model of an infused drug.
An additional hypothetical effect compartment was proposed to represent the
lag between plasma drug concentration and drug response. The amount of drug
in this compartment is represented by qe. The effect compartment receives drug
from the central compartment by a first-order process and it is regarded as a virtual
additional compartment. Therefore, the drug transfer frequency for Propofol from
the central compartment to the effect site-compartment is equal to the frequency
of drug removal from the effect-site compartment ke0 = k1e = 0.456[min−1] and
we have that:
C˙e(t) = Ke0(Ce(t)− Cp(t)) (5.9)
with Ce = qe/V1 called the effect-site compartment concentration, and Cp =
q1/V1 called the plasma concentration in the first compartment. The relation be-
tween the effect site concentration Ce and BIS is given by a nonlinear sigmoid Hill
curve [129]:
Effect = E0 − Emax Ce(t)
γ
Ce(t)γ + C
γ
50
(5.10)
where E0 is the value of the effect before the surgery (i.e. when the patient is
awake), Emax is the maximum effect that can be achieved by the infusion of
Propofol, C50 is the Propofol concentration at half of the maximum effect, and
γ is a parameter which together with the C50 determines the patient sensitivity to
the drug.
There are many assumptions regarding the modeling approach. Marsh et al.
[130] considered weight as the only variable which covariates. A few years later
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Kataria et al. [131] also included parameters such as age and gender as covariates.
Later on, a linear relationship between the PK of the drug and the rate of infu-
sion has been developed [132]. The conclusion of some other researches was that
elderly patient are more sensitive to analgesic drugs than younger patients [133].
In the work of Vuyk et al. [134] a more accurate three compartmental PK model
which takes into account age and weight parameters as significant covariates is
described.
Fractional pharmacokinetics was first introduced by Dokoumetzidis and Macheas
[12]. Their work presents the application of fractional calculus for a simple one
compartmental model. Later on, this approach has been extended to a multi-
compartmental model [15]. Popovic et al. [15] generalized the classical first order
compartmental model by replacing the left hand side of the equation with fractional
derivatives. Standard arguments imply that the equations which are determined by
the mass balance in compartments have the following form [9].
τn1−11 D
n1q1(t) = K21q2(t) +K31q3(t)−K12q1(t)−K13q1(t)−
K1eq1(t)−K10q1(t) + U(t)
(5.11)
τn2−12 D
n2q2(t) = K12q1(t)−K21q2(t)−K20q2(t) (5.12)
τn3−13 D
n3q3(t) = K13q1(t)−K31q3(t)−K30q3(t) (5.13)
τne−1e D
neqe(t) = K1eq1(t)−K0eqe(t) (5.14)
where: τi represents the characteristic time of the i − th compartment, expressed
in seconds, i = 1, ...., n and Kij , for i, j = 1, ...., n are standard diffusion coef-
ficients having the dimension 1/s. The introduction of τi leads to the dimensional
homogeneity of fractional rate equations. Dividing equations (5.11)-(5.14) by τnii
and redefining the constants we obtain the following fractional order differential
equations.
Dn1q1(t) = k21q2(t) + k31q3(t)− k12q1(t)− k13q1(t)−
k1eq1(t)− k10q1(t) + U(t)
(5.15)
Dn2q2(t) = k12q1(t)− k21q2(t)− k20q2(t) (5.16)
Dn3q3(t) = k13q1(t)− k31q3(t)− k30q3(t) (5.17)
Dneqe(t) = k1eq1(t)− k0eqe(t) (5.18)
with n1 = n2 = n3 = n and the constants were redefined according to relation
(5.19).
kij =
Kij
τn1−1i
(5.19)
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where kij are the constants depending on the rate of absorption, elimination, tis-
sue take up, characteristic and inactivation of drug. One of the characteristic of
fractional derivatives is the ”memory effect” term. It is well known that the state
of many systems (biological, electrochemical, viscoelastic, etc.) at a given time
depends of their configuration at previous time [135].
For compartmental models a general numerical solution of the fractional dif-
ferential equation Dnt y(t) = f(y(t), t) can be expressed as:
y(tk) = f(y(tk), tk)h
n −
k∑
j=1
cnj y(tk−j) (5.20)
where: tk = kh, for k = 1, 2, 3....N samples and h is the sampling time. For our
case the numerical solution is obtained by applying equation (5.20) on equations
(5.15)-(5.18) and it has the following form:
q1(tk) = (k21q2(tk) + k31q3(tk)− k12q1(tk)− k13q1(tk)−
k0eqe(tk)− k10q1(tk − 1))hn −
k∑
j=1
cnj q1(tk−j) (5.21)
q2(tk) = (k12q1(tk)− k21q2(tk)− k20q2(tk−1))hn −
k∑
j=i
cnj q2(tk−j) (5.22)
q3(tk) = (k13q1(tk)− k31q3(tk)− k30q3(tk−1))hn −
k∑
j=i
cnj q3(tk−j) (5.23)
qe(tk) = (k1eq1(tk)− k0eqe(tk−1))hn −
k∑
j=i
cnj q3(tk−j) (5.24)
PD model describes the relationship between drug concentration and its clini-
cal effect. Similar to PK modeling the influence of parameters such as gender or
age were also investigated. Regarding the gender influence on the PD of analgesic
drugs has been studied [136] and the conclusion was that there are significant dif-
ferences between male and female patients on the response to analgesia. Drugs
pharmacodynamics are described by an additional effect-site compartment (see
Figure 5.1) and a non-linear relationship between drug concentration and drug ef-
fect. This relationship is often modeled by a sigmoid function [129]. The PD
model relates the concentration provided by the PK model to the observed effect.
Due to its nonlinearity PD models represent the challenging part of PK/PD models.
To deal with this nonlinearity Hill equation is widely used. Hill equation has been
extensively used to analyze quantitative drug-receptor relationship. Moreover, Hill
equation is used in PK/PD modeling to describe the nonlinear drug dose response
relationship. The basic expression is given by equation (5.10).
5-8 PK-PD MODELS OF DRUG UPTAKE AND DRUG EFFECT
5.2 Pharmacodynamic model (interaction model)
The relation between the amount of drug administered and the entity of its effect,
referred to as pharmacodynamics, is often modeled by a sigmoid function [129]. A
sigmoid curve can be adopted to describe drug pharmacodynamics. The PD model
relates the concentration provided by the PK model to the observed effect. The
classic and most commonly used PD models is the sigmoid pharmacodynamic re-
lation where the parameters are functions of the drug ratio (θ) [129]. For one drug,
the model can be represented by equation (5.10), also known as Hill equation:
When a combination of two drugs A and B is used, equation (5.10) becomes
equation (5.25) and a ratio (θ) of their normalized concentrations is defined.
Effect = Emax(θ)
UA+UB
U50(θ)
1 + UA+UBU50(θ)
(5.25)
θ =
UB
UA + UB
(5.26)
UA =
CA
EC50A
;UB =
CB
EC50B
(5.27)
Emax(θ) = EmaxA + (EmaxB − EmaxA − βEmax) ∗ θ + βEmax ∗ θ2 (5.28)
γ(θ) = γA + (γB − γA − βγ) ∗ θ + βγ ∗ θ2 (5.29)
U50(θ) = U50A + (U50B − U50A − βU50) ∗ θ + βU50 ∗ θ2 (5.30)
and considering that U50A = U50(θ = 1) = 1 and U50B = U50(θ = 0) = 1,
equation (5.29) simplifies to:
U50(θ) = 1− βU50) ∗ θ + βU50 ∗ θ2 (5.31)
where:
• U50(θ) represents the potency of the drug combination relative to the nor-
malized potency of each drug by itself;
• Emax, U50, and γ are expressed as functions of the drug ratio (θ), see equa-
tions (5.28)-(5.31);
• UA and UB are the normalized concentrations of drugs A and B;
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• EmaxA, γA, U50A, and EmaxB,, γB , U50B are the pharmacodynamic pa-
rameters for the two drugs A and B;
• βEmax, βγ , and U50(θ) represent the interaction parameters;
• Emax(θ), γ(θ) and U50(θ) are the corresponding pharmacodynamic param-
eters for the sigmoid curve.
Figure 5.2 shows the block diagram of the BIS model. The objective is to
describe the relationship between the drugs effect concentrations and its effect.
Bruhn et al. [137] used an interaction model to relate the electroencephalographic
parameter values (including BIS) to the effect concentrations of hypnotic and opi-
oid drugs. This model model has been proposed by Minto et al. in a previous
study [129].
Figure 5.2: Block diagram of BIS model.
In the case of combined administration of two or more drugs, the potential in-
teractions must be considered. Different approaches to drug interaction modeling
have been developed. A common approach [129] is based on the use of response
surfaces, where a combination of drugs is regarded as being a new drug with its
own sigmoid pharmacodynamic concentration effect relation. In Figure 5.3 the
global effect as a result of simultaneous administration of drugs 1 and 2 is given.
As a conclusion one may say that PK-PD data and the link between them can
be model in two ways: either simultaneously, either separately [138]. In most sit-
uations PK models are better understood and defined than PD model and therefore
an intermediate step is preferred. In this way, the pitfall due to poor PD data or
wrong model selection can be avoided. However, for both mechanism-based and
descriptive models, only rigorous validation procedures can ensure dose- and time-
independence of PD parameters asEmax andEC50. Using equations (5.21)-(5.24)
one obtains the results presented in Figures 5.4 and 5.5.
A detailed description regarding the model parameters is given in [126, 127].
From Figure 5.4, it can be concluded that the order of the derivatives n determines
the decay of the numerical solution. Notice that for n < 1, the decrease of the
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Figure 5.3: Example of response surface for the combined effect of two drugs.
Figure 5.4: Drug concentration profile in compartment blood, muscle and fat.
amount in compartment 1 (plasma) is faster than in the integer order model (n =
1.0). This is a very important property of the fractional-order model that can be
used to capture inter-patient variability.
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Figure 5.5: Drug concentration profile in compartment blood, muscle and fat.
5.3 Anomalous Kinetics
The PK literature is dominated by compartmental models of drug dynamics in
human body, for a wide range of medical application or treatment [12, 139]. The
mamillary compartmental model with single compartment seems to be the simplest
representation of drug uptake and clearance, with the amount of a drug defined by
a simple ordinary differential equation (ODE) relation:
dA(t)
dt
= −k10A(t) (5.32)
with A(0) the dose of bolus intake and K10 is the clearance rate constant. The
solution, A(t) = A(0) · e−k10t. However, usually 2-3 compartments are taken
into account and as to specify the heterogeneity between the blood, muscle and
fat tissue dynamics. It turns out that characterization as a function of time implies
a negative power function derived from plasma drug concentration profiles [13].
Nevertheless, triexponentials with power and gamma functions were successfully
fitted to power law data and results for several drug pharmacokinetics reported in
literature [13]. An important decision at that time was to make observations on
log-log plots with y- data and x-time axis. A limitation of the data intervals led to
the use of gamma functions, assuming homogeneous distribution of drug into the
compartmental volume. The necessity of several exponential terms to fit the data
in linear regression algorithms seemed at the time unavoidable.
Later on, the necessity of a recirculation mechanism was to account for ob-
served fluctuations in the time decay of a drug PK [140, 141]. The assumption
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that compartmental models were homogeneous no longer fit the observed data.
However, since the tools used to model the dynamical variability were ODEs, aug-
menting the model with a residence time information was a solution at hand. How-
ever, care must be taken when considering transient and residence times, since the
two notions are different in PK specifications [140]. As stated in [140], classical
compartmental models fail to explain the effect of different sampling sites, due to
concentration differences across the various biological tissues. The units of the
PK compartmental models are confined to exponentially distributed transit times.
By contrast, recirculatory models may be characterized by any parametric or non-
parametric class of drug transit time distributions. The choice of the model type is
thus important, and it greatly depends on the objective it may serve.
In an effort to circumvent the choice of the model type, non-Markovian com-
partmental models were proposed [142]. Random particle distribution and transfer
based on retention times seem adequate in capturing heterogeneous dynamic ef-
fects. The authors provide an adapted view of the models from Weiss in assuming
a three compartmental PK model whereas one compartment is seen as a distri-
bution of pseudo-compartments with different retention times. Clearly this is a
more realistic approach since it enables phenomenological observations of drug
accumulation and/or late recirculation loops. Still, oscillatory behaviour in drug
concentration profiles for a single bolus intake are ignored. A conceptual view of
such model representation is given in Figure 5.6. Tissue trapping was addressed
Figure 5.6: Distributed compartmental PK models. A three-compartmental scheme is
given with classical two compartments on the right side combined with a distributed drug
retention times compartment on the left side. Notice that intermediate drug profiles x,y,z
may vary locally due to tissue trapping. Note that all drug fluxes denoted by arrows may
have different dynamics (FDEs) as opposed to classical ODEs.
by Weiss later in [21], by proposing a non-classical PK model describing well the
persistently increasing plasma concentration time curve during long term treatment
and the washout curve following terminal therapy. The long tailed tissue residence
time distribution is incorporated by means of a recirculatory model. Weiss [21]
also acknowledges the anomalous kinetics and the fractal scaling property in char-
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acterizing amiodarone drug dynamics. A conceptual schematic of such distribution
is given in Figure 5.7.
Figure 5.7: A conceptual view of distribution of tissue dynamics with various residence
times and drug trapping areas.
A decade later, emerging tools from fractional calculus enabled a new wave
of PK compartmental modelling theories, indicating some important flaws in the
classical PK models. For example, multi-compartmental kinetics with fractional
differential equations (FDEs) following consistent physiological mass balance ra-
tionale have been reported in [11]. Numerical methods to efficiently compute these
equations are largely available to the community and simulations no longer pose
tedious implementations. The great revelation of these numerical studies was that
the presence of a transfer rate of fractional order produces a non-exponential termi-
nal phase, while multiple dose and constant infusion systems never reach steady-
state, resulting in drug accumulation. The latter is a life-threatening issue for the
patient and imposes a critical observation on the usefulness of previous PK com-
partmental model definitions. Deep tissue trapping may account for observed sec-
ondary effects days, weeks and months in patients who undergone surgery with
general anaesthesia, or following cancer treatment therapies. These new theoreti-
cal concepts and PK models may enable a different, novel perspective of drug drug
kinetics. Such models more accurately predict the observed drug profiles and can
provide an new basis for optimizing treatment.
Drug tissue trapping has been addressed also in [143] using fractional kinetics
and data on amiodarone from [21]. Significant differences in linear or logarith-
mic drug intake profiles have been observed in numerical simulations, suggest-
ing drug accumulation and inherent side affects in patient well-being. The paper
from [143] proposes a dosing regime to stabilise the plasma concentration of amio-
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darone when fractional PK models are used. .
Still, among all the previous works related to introducing anomalous kinetics
and fractional PK compartmental models one cannot but notice the fact that some
effects of drug trapping and releasing are yet unaccounted for.
Anomalous subdiffusion is represented by:
< X2(t) >≈ tn (5.33)
with 0 < n < 1. Subdiffusion could be used to model molecules of drug trapped
in deep tissue for long times. The subdiffusive fractional Fokker-Planck equation
can be employed as from [144]. Let p(x, t) be the density function for finding the
particle in the interval (x, x+ dx) at the time instant t; then
∂p
∂t
= −∂(vn(x)D
1−n
t p)
∂x
+
∂2(Dµ(x)D
1−n
t p)
∂x2
(5.34)
in which Dn(x) is the fractional diffusion and vn(x) is the drift, with n < 1, and
the Riemann-Liouville derivative is defined as
D1−nt p(x, t) =
1
Γ(n)
∂
∂t
∫ t
0
p(x, u)du
(t− u)1−n (5.35)
where we see the difference between the standard Fokker-Planck equation and the
its fractional version by means of the rate of relaxation
p(x, t) −→ pst(x) (5.36)
When using this equation to extract residence times, on the long term, as t −→∞
the non-homogeneous variations of the parameter µ as a function of space should
be carefully checked. Recent studies by [144–146] reported that the diffusion
coefficient is a nonlinear function of the nonlinear reaction rate. In this model
[146] the escape rate T of a particle from a position is modeled as a decreasing
function of density ρ(x, t):
T (τ, ρ) = n(τ)
1 +Aρ(x, t)
(5.37)
which describes the phenomenon of con-specific attraction: the rate at which indi-
vidual molecules or particles of drug emigrate from the point x is reduced due to
the presence of many other con-specifics. The rate parameter µ(τ) is a decreasing
function of the residence time:
n(τ) =
n0
τ0 + τ
(5.38)
where n0 and τ0 are positive parameters. This particular choice of the rate has been
motivated by non-Markovian crowding: the longer the particles stay in a particular
site, the smaller the escape probability to another site (e.g. fat).
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5.4 Revisited FDE PK Model
It has been suggested that instead of combining power law and exponential func-
tions to account for anomalous kinetics, it is more efficient to use the Mittag-
Leffler function [11]. This function has the capability to follow the stretched expo-
nential for small times and the power function for long times, thus it is appropriate
for characterizing both the short and the long time scales of drug concentration
profiles. A classical two-compartmental model is given by the following ODEs:
dA1(t)
dt = −k12A1(t) + k21A2(t)− k10A1(t)
dA2(t)
dt = k12A1(t)− k21A2(t)− k20A2(t)
(5.39)
The correct fractionalisation of equation (6.29) maintaining mass balance, is given
by:
dA1(t)
dt = −k12C0 D1−n1t A1(t) + k21C0 D1−n2t A2(t)− k10C0 D1−n3t A1(t)
dA2(t)
dt = k12
C
0 D
1−n1
t A1(t)− k21C0 D1−n2t A2(t)− k20C0 D1−n3t A2(t)
(5.40)
with kij rate constants and initial conditions A1(0) = dose, A2(0) = 0 which
account for bolus injection and no initial amount in peripheral compartment. Here,
the fractional order of the Caputo fractional derivative represents the heterogeneity
of the diffusion dynamics [5].
Take for instance the two-compartmental PK model from Figure 5.8. Clear-
ance and diffusion from 1-2 is considered as a classical (ODE) whereas diffusion
2-1 is fractional (FDE), with n < 1 to account for deep tissue trapping of the drug.
The model can be described by the following set of equations:
Figure 5.8: Two-compartmental PK model representation. The continuous arrows denote
ODEs, whereas dashed arrows denote FDEs.
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Figure 5.9: Frequency response of (5.42) for various values of n.
dA1(t)
dt = −(k12 + k10)A1(t) + k21C0 D1−nt A2(t)
dA2(t)
dt = k12A1(t)− k21C0 D1−nt A2(t)
(5.41)
The model has been transformed to the Laplace domain and solved for A1 using a
numerical inverse Laplace transform program in Matlab as described in [11]. The
solution is given by:
A1(s) =
dose(sn + k21)
(s+ k12 + k10)(sn + k21)− k12k21 (5.42)
For values n < 1 the solution behaves essentially as a first order system, i.e.
two poles of which one is cancelled by a zero at high frequencies. Suppose now
that the values of na may increase above 1. The Bode plot of the transfer func-
tion is given in Figure 5.9 for various values of n, simulated with parameters as in
table 5.1. From an engineering point of view, this non-rational transfer function
changes dynamic behaviour from a first order to a second order system. In order
to verify the time response of these transfer functions, it is necessary to use an in-
verse Laplace transform for non-rational polynomial representations. A numerical
algorithm in Matlab has been proposed in [11], and it is used to simulate the results
reported in this paper as well. The time domain simulations are given in Figure
5.10.
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Figure 5.10: Time domain behaviour of the transfer function from (5.42) for various values
of n.
5.5 Illustrative Example
A dynamic concentration profile (see Figure 5.10) for the drug Amiodarone taken
from [21] has been mimicked for simulation purposes. The model from (5.42)
has been identified to fit data which poses characteristics observed in real concen-
tration values reported in literature. Of particular importance are the oscillatory
dynamics which relate to recirculation effects as discussed above.
Using the nonlinear least squares algorithm in Matlab provided by the function
lsqnonlin the parameters have been identified as in table 5.2.
The potential of increasing α > 1 is observed in capturing possible variations
in the concentration profiles, when compared to the result for α < 1 sketched in
Parameter Value
k10 (days−1) 1.49
k12 (days−1) 2.95
k21 (days−α) 0.48
α (-) (0.5,1.5)
dose/V (ng/ml) 4.72
Table 5.1: Estimated model parameters used in simulation, with k the transfer rates
between the compartments and clearance rate, and V the volume of the central
compartment.
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Figure 5.11.
Figure 5.11: Variations obtained with sub- and supra- unitary values of α.
From this analysis, we were expecting to see oscillation (due to drug accumu-
lation) but given the missing data in literature we could not reach to this conclu-
sion and the results presented here are at this moment speculations. Of course,
the model may be further tuned on real data profiles. It should be also noted that
the amount of variability as a function of time differs from one patient to another,
hence the model parameters could be fit in an individualised PK model framework.
The model with the solution given in (5.42) has some limitations in capturing
all oscillatory dynamic profiles. This is due to the fact that only two compartments
have been used, without recirculation, and without taking into account heterogene-
ity in the tissue. The distributed parameter compartmental models, as depicted in
Figure 5.6, may potentially be employed to circumvent this limitation.
Parameter Value
k10 (days−1) 1.7
k12 (days−1) 2.5
k21 (days−α) 0.6
α (-) 1.5
Table 5.2: Identified model parameters used in simulation from (5.42) for a fixed dose of
4.7268 (ng/ml).
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5.6 Discussion and Perspectives
Naturally, tissue porosity, molecular binding and permeability vary within the or-
gan, within the system and within the assumed compartment. Taking tissue speci-
ficity into account when modelling PK dynamic profiles may lead to increased
model complexity. A trade-off between the usefulness and computational effi-
ciency of such models must be made when evaluating the model objectives. If
prediction for treatment optimisation is envisaged, then one may include as many
details as possible to account for a personalised healthcare plan. If mere evalu-
ation of dosing profiles and observational studies are involved, tissue specificity
may be limited to the strictly necessary number of details (e.g. Occam’s Razor ap-
proach). Obviously, large population data sets will be necessary to provide some
reference baseline values for initial start-up. However, if data is available, data
driven modelling/identification may be performed and model parameters tuned to
fit the specificity of the case.
Applications of augmented PK models with FDEs are numerous and not lim-
ited in the number of turns. One may freely consider their application to modelling
any drug PK dynamics. Multiples types of dosing intake may be assumed, either
as a single type, or as combinations hereof: single dose, bolus, multiple dose, con-
tinuous infusion. When using FDEs in PK models, care must be taken for intake
profiles may lead to drug accumulation and possibly over-dosing in some time in-
tervals. Linear or power-law dosing profiles may be investigated to optimally use
the dynamic model properties.
As such, time FDEs have been considered hitherto. However, tissue hetero-
geneity is also structural, geometric, and not only present in dynamic fluctuations.
It may be worth considering introducing a time-space mathematical formulation
(e.g. by employing fractional order space derivatives) to account for drug intake
whereas time and location may be specified. This is of great importance in pathol-
ogy cases, where changes in tissue structure and morphology affects directly the
dynamic profiles of drug diffusion, permeability and molecular binding. Specific
structural changes with disease may also reveal various paths of deep tissue trap-
ping of drug and latency nodes which could explain effects observed in long-tailed
observations.
5.7 Summary
In this chapter the existing compartmental modelling approaches have been re-
visited and their usefulness has been extended by employing emerging tools from
fractional calculus . Undoubtedly, the fractional kinetics approach outperforms the
classical ODE models while maintaining the link to physiological phenomena. It is
worth mentioning that the assumption of a homogeneous compartment representa-
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tion is no longer limiting in view of modelling objectives. Instead, tissue trapping
and heterogeneous resident times may be taken into account by using distributed
compartmental models with various diffusion rates. The combination of classical
PK models and with fractional PK models is then the natural next step in the quest
to improve their ability to mimic complex observed physiological phenomena.
6
Proposed Models and Their Validation
In this chapter the proposed models to characterize the nociceptor pathways are
presented. These models have been validated (in vitro and in vivo) and have the
potential to unlock the current state of art in this specific area of applications.
The main publications where this work has been presented are:
1. D. Copot, R. De Keyser, J. Juchem, C. Ionescu, Fractional order impedance
model to estimate glucose concentration: in vitro analysis. Acta Polytech-
nica Hungarica, 14(1), 207-220, 2017.
2. D. Copot, C. Muresan, R. De Keyser, C. Ionescu, Fractional order modeling
of diffusion processes: a new approach for glucose concentration estimation,
International Conference on Automation, Quality and Testing, Robotics,
Cluj-Napoca, Romania, 19-21 May, 407-712, 2016.
3. D. Copot, R. De Keyser, C. Ionescu, In vitro glucose concentration esti-
mation by means of fractional order impedance models, IEEE International
Conference on Systems, Man, and Cybernetics (SMC), 9-12 October, Bu-
dapest, Hungary, 2711-2716, 2016.
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6.1 Introduction
Nociceptor pathway: relation between potassium channels and pain signalling
Potassium is one of the most common cation in the body and the principal intra-
cellular cation. Approximately 3500 mmol of potassium are present in the body.
The distribution of Na+ and K+ can be thought of as opposite: one is in high
concentration and the other is at low concentration. Sodium is the most prevalent
cation in the extracellular fluid (ECF), with a normal level of around 140 mmol/L,
but has a typical intracellular concentration of around 10 mmol/L. In contrast,
potassium is the most prevalent cation in the intracellular uid, with a concentra-
tion around 150 mmol/L and about 5 mmol/L in the ECF [81, 147]. Because the
intracellular space is the largest fluid compartment in the body, this makes it the
most abundant cation overall. Hence, Na+ and K+ can only cross where specific
carrier proteins allow them to do so. Excitable cells can change their permeability
to allow the in flux and efflux of ions that constitute an action potential. At rest,
the large concentration gradients for Na+ and K+ are maintained by the action
of Na+/K+ pump [147]. This also maintains the net negative resting membrane
potential, since it involves a net transfer of one positive charge out of the cell on
each cycle [148, 149].
The observed increase in potassium concentration in the ECF varies between
0.1 and 10.0 mmol/L and depends on stimulation frequency, intensity, and duration
[150]. An increase of 0.1-0.5 mmol/L has been found after a single electrical
stimulus applied to the dorsal root, to peripheral nerve, or after a single adequate
stimulus (light touch or pinch) applied to the skin. Repeated stimulation leads to
summation of responses. For example, an increase of about 6-7 mmol/L was found
in spinal cord after 15 seconds of high-frequency electrical stimulation (100 Hz) of
peripheral nerves. When stimulation is continued, no greater changes in potassium
concentration are found because a steady state is established, which is the result
of concurrent release and clearance of K+. This so called ”ceiling level” can be
exceeded only during epileptic seizures, anoxia or spreading depression, whenK+
can reach levels as high as 20-50 mmol/L [147,149]. Because of the threshold, the
action potential can be likened to a digital event, i.e. it either happens or it does not.
If the threshold is not reached, then no action potential occurs. Action potentials
are based on all or nothing law: either the membrane reaches the threshold and
everything occurs as described or the membrane does not reach the threshold and
nothing else happens.
While an action potential is in progress, another one cannot be initiated. That
effect is referred to as the refractory period. There are two phases of the refractory
period: the absolute refractory period and the relative refractory period. During
the absolute phase, another action potential will not start. This is because of the
inactivation gate of the voltage-gated Na+ channel. Once that channel is back to
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its resting conformation (i.e. less than -55 mV), a new action potential could be
started, but only by a stronger stimulus than the one that initiated the current action
potential. This is because of the flow of K+ out of the cell. Because that ion is
rushing out, any Na+ that tries to enter will not depolarize the cell, but will only
keep the cell from hyperpolarizing [150, 151].
6.2 Cole Cole model
Biological tissues are complex structures characterized by dynamic processes oc-
curring at different lengths and time scales. Simple exponential relaxation models
cannot adequately describe the behavior of such materials, as they do not con-
sider the interactions among various relaxing phenomena and memory effects
[152]. Non-integer formulations of the Debye relaxation models [153] are of-
ten necessary to account for slower and faster molecular rearrangements that take
place within the microscopic, mesoscopic and macroscopic organization of the
phenomena [152]. Therefore, to characterize such complex structures, electrical
impedance spectroscopy and more specifically Cole-Cole models seem to be a
good candidate.
The Cole-Cole generalize the Debye equation [152,154,155] and these models
can be described in term of fractional order-differential equations [8, 119, 156,
157] often refereed to fractional calculus. Fractional calculus denotes the branch
of calculus that extend the concepts of integrals and derivatives to non-integer
and complex orders. This filed dates back to year 1695 and it has been during
recent decades that FC was found to play a fundamental role in modeling several
important physical phenomena. As a result, this emerged as an important tool
which have been adopted in a wide range of topics, from dynamics of biological
structures up to mechanical and electrical systems [14, 158].
The mathematical model of electrical properties of cell membranes, based on
impedance measurements at multi frequency alternative current, was firstly formu-
lated by Cole in 1940 [159]. Magin [119] derived and generalized Cole equation
using fractional calculus. His model comprises three hypothetical circuit elements:
a low frequency resistor R0, a high-frequency resistor R∞ and CPEn. This cir-
cuit can be visualized as two serial connected elements, where the first one is R
and the second one is (R0 − R∞)||CPE∞. We denote the second element as the
reduced Cole type element. The complex impedance described by Cole model is
given by the following equation [159].
Zα(ω) = R∞ +
R0 +Rinf
1 + (jωτn)n
(6.1)
with the characteristic relaxation time, according to Magin, positive constant:
τα =
n
√
Cn(R0 −Rn) (6.2)
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where all coefficient are material constants independent of frequency.
Applied alternating voltage to the system is:
V (t) = V0exp(jωt+ θ) (6.3)
with V0 the voltage amplitude, θ is the phase angle between the voltage and the
current, current passing through the system is i(t) = i0exp(jωt). The Impedance
of the system is given by V (t) = Zα(ω)i(t) with the relations describing the
system with fractional Weyl derivative Dn(jω)n}:
1 + (τn)
αDn)V (t) = (R∞(τn)Dn +R0)i(t) (6.4)
If one takes into account geometrical properties of the physical system, such
as surface of electrode and distance between them, complex dielectric constant
becomes complex capacitance (C). Note that the in the theory of alternative cur-
rent the admittance Y is described by formula Y = jωC. Therefore, the equation
above describes frequency dispersion of complex resistivity in the case when ge-
ometry is not taken into account.
Formal replacement in equation above is done by:
(τα)
αDα → (τα∗;βK)α∗;β (6.5)
where n∗;β denote the real and imaginary parts of the fractional operator respec-
tively. Notice that for n∗ = na and β = 0, this notation becomes the fractional
order of real numbers (i.e. classical fractional calculus). Furthermore, for integer
values of , we have then classical integer order calculus theory. By introducing
new parameters for resistance in complex plane R∗0, R
∗
∞ we can rewrite in general
form the equation as:
(1 + (τn∗K)
n∗;β)V (t) = (R∗β(τn∗;βK)
α∗;β +R∗0)i(t) (6.6)
and using the following change of notation Zα(ω) → Zα∗;β(ω) the following
equation is obtained:
Zn∗;β(ω) = R
∗
∞ +
R∗0 −R∗∞
1 + (jωτn∗;β)n
∗βlog(jωτn∗;β)
(6.7)
and this equation represents the new generalized Cole model. This model has five
physical and phenomenological parameters: n∗, β, τn∗;β , R∗0, R
∗
∞. The meaning
of the β parameter describes the relaxation properties of dielectric phenomena of
the medium; the constant R∗0 and R
∗
∞ are the corresponding resistances, hence
limβ → R∗0 = R0; limβ → R∗∞ = R∞. and thus we can note that for small
values of β we have that α∗ ≈ α,R∗0 ≈ R0, R∗∞ ≈ R∞. Notice that in the
complex plane paradigm, the meaning of R∗0 and R
∗
∞ are different since the mem-
bers βlog(jωτn∗;β) and thus Zn∗;β(ω) have different asymptotic behaviour when
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Figure 6.1: Elipsoid form of polar plot indicates existence of remnant memory (nonlinear
effects).
ω → ∞ or ω → 0. In terms of Cole diagram, for values of β 6= 0, changes in
Zn∗;β(ω) are not circular (Figure 6.1), hence it exhibits a nonlinear dispersion of
impedance.
The assumption that the change in conductive properties of electrical circuits
is only in CPE leads to the following equation (generalized CPE):
ZCPEα(ω) =
1
Cα(jω)α
→ ZGCPEα∗;β(ω) =
1
Cα∗;β(ω)(jω)α
∗+βlog(jωτα∗;β)
(6.8)
where we clearly see the nonlinear scaling of frequency for dispersion of impedance.
Moreover, ifα∗, β vary, then this implies further non-linearization with non-constant
parameters. Hence, this model has significant advantages for capturing time vary-
ing changes in the skin impedance. Equation (6.8) introduces the generalisation of
CPE (GCPE). The electrical circuit comprising of the element R∗∞ in serial con-
nection with the elements R∗0 - R
∗
∞ and ZGCPEα∗;β(ω) which depends on the
element R∗0 - R
∗
∞.
Impedance measurements of the samples were performed with a Solatron Mod-
ulabXm impedance analyzer (Solatron Analytical, UK), see Figure 6.2. The impe-
dance cell consisted of a plastic cylindrical tank with an inner diameter of 20 mm
and a length of 30 mm. Several artificial samples at different potassium concen-
tration have been prepared (considering the baseline concentration in the human
body). In normal physiological conditions potassium concentration in the extracel-
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lular fluid is about 4-5 mmol/L. Deionised water and potassium chloride was used
to prepare the samples. Through the Solatron analyzer a 100 mV r.m.s. sinusoidal
voltage has been applied to the outer couple of electrodes of the measurement
probe which was immersed into the glass tube containing the analyzed sample.
Impedance of the samples has been analyzed in the 1Hz-0.1MHz frequency range.
Figure 6.2: Solatron ModulabXm impedance analyzer.
ModuLab XM ECS is an Xtreme Measurement electrochemical test system
that is capable of measuring ultra-low, micro-ohm impedance cells (latest gener-
ation batteries and fuel cells, for example), while able to accurately characterize
ultra-high impedance corrosion coatings at the other extreme. The system uses a
unique AC calibration method that ensures ultimate accuracy in all cases.
The results obtained using the Cole-Cole model (6.7) are given in Figure 6.3.
(a) (b) (c)
Figure 6.3: Cole-Cole model (blue line) and measured data (red line) for different
potassium concentrations (a) 3.2 mmol/L; b) 4.9 mmol/L and c) 7.5mmol/L). The analysis
has been performed in the frequency interval 1Hz - 0.1 MHz
CHAPTER 6 6-7
6.3 Non-parametric Impedance model
The ANSPEC-PRO device records the voltage V (t) (V) and current I(t) (A) sig-
nals measured in the hand palm of the subject. The device is depicted in Figure
6.4 and a detailed description is presented in Appendix A.
Figure 6.4: The developed prototype to enable a model of the nociceptor pathway.
To the measured signals non-parametric identification methods can be applied
to extract the cross-spectral power density of the input and the output of the system.
Given the input is of sinusoidal type (A sin(ωt)), the impedance is a frequency
dependent complex variable evaluated as [14]:
Z(jω) =
SUU (jω)
SUY (jω)
(6.9)
where SXY (jω) denotes the cross-correlation spectra between the various input-
output signals, ω = 2pif is the angular frequency and j =
√−1, the result being
a complex variable. The derivation of (6.9) from the measured signals is detailed
in [14].
The procedure followed for measurements and the preliminary results are pre-
sented hereafter. Following the measurement protocol described in Table 6.1 three
different study cases have been investigated.
• Case 1 - Perform two consecutive measurements to investigate the device
repeatability and if pain persists. Sensors are placed on the right hand and
the pain stimulus is applied at the same location (i.e. same hand).
• Case 2 - Perform one measurement on a different day at the same time as
the first case to investigate if the initial conditions have changed. The same
location for the sensors and pain stimulus is used.
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• Case 3 - Perform one measurement on a different day to investigate the loca-
tion. In this case the sensors are placed on the right hand palm but the pain
stimulus is applied on the left hand.
Minute Nociceptor stimulation
0-2 Absent (NP)
2-3 Present (P)
3-6 Absent (NP)
6-7 Present (P)
7-10 Absent (NP)
Table 6.1: The consecutive steps in the 10 minute pain protocol
The measurement requires three electrode: two current-carrying electrodes and
one pick-up electrode. The latter is an electrode picking up the voltage without
carrying any currents, hence, no polarization occurs. All electrodes were placed
on the palmar side of the hand (see Figure 6.5).
Figure 6.5: Placement of the electrodes during proof-of-concept measurements; two
current-carrying electrodes (white, red) and one pick-up electrode (black)
The excitation signal is a multisine signal with 29 components in the frequency
interval 100-1500 Hz, with step interval of 50Hz. This signal is send to the patient
and the corresponding output is acquired. The sampling frequency is 15 KHz. The
multisine signal is send with an amplitude of 0.2mA, still a factor 5 below the
maximum allowed for patient safety [160].
The above described case studies have been investigated on a group of 10 vol-
unteers. The biometric parameters (average) of the investigated subjects are: Age
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(30 years); Height (1.73); Weight (73) and BMI (24). In Figures 6.6 - 6.7 the re-
sults obtained for one volunteer are presented. The results obtained for the other
volunteers can be found in Appendix B.
The measured signals are filtered for noise prior to apply non-parametric iden-
tification methods [161]. Given the input is of sinusoidal type (A sin(ωt)) impedan-
ce is a frequency dependent complex variable evaluated as described in (6.9).
Classical periodogram filtering technique has been applied with no overlapping
interval, with windowing function Blackman implemented in Matlab environment
[161]. The impedance is then evaluated every minute from online data streaming
and plotted against frequency. This is then a frequency response either in complex
form (Real and Imaginary Parts), either in Bode plot form (Magnitude and Phase).
Figure 6.6: Impedance in its complex representation for the first study case (left: first
measurement; right: second measurements).
In Figure 6.6-left the results for the first case study (first measurement) are
shown. From here it can be noticed that the no pain (NP) situations are signifi-
cantly different in amplitude than the pain (P) situations. This indicates that the
impedance changes when a pain stimulus is applied. In Figure 6.6-right the results
obtained after the second (consecutive) measurement are presented. Here we can
notice that the NP and P situation are no longer separated. This indicates that pain
persists from the first measurement (i.e. memory effect!). This is a remarkable
finding to justify the use of fractional order impedance models. In Figure 6.7-left
the results for the second study case are presented. Also in this case there is no
significant difference between NP and P situations which indicated that the initial
conditions in comparison with the previous day have changed (research is cur-
rently ongoing to investigate this hypothesis). Although we may tend to draw the
same conclusions as for Figure 6.6-left (i.e. pain memory), this cannot be the case
since the volunteer received no pain stimulus before.
In Figure 6.7-right the results for the third case study are presented. In this
case, when the applied stimulus is on a different location that the sensor placement,
we may draw the same conclusions as for the first case study (first measurement).
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Figure 6.7: Impedance in its complex representation for the second (left) and third (right)
study cases.
This means that the sensor location is not crucial (ongoing research investigates
this hypothesis). However, in this particular case it can be noticed that the first
pain stimulus has an impedance higher than for the NP situations (as expected) but
for the second pain stimulus the impedance is lower than for the NP situations.
Next, only the pain situations for each case study are presented in Figures
6.8 - 6.9. For the first measurement (Figure 6.8-left) it can be seen that the first
pain stimulus is higher in amplitude than the second pain stimulus. This indicates
that pain persists from one stimulus to the other (i.e. memory). However, when
a second consecutive measurement is applied the opposite is valid (i.e. the first
stimulus is lower in amplitude than the second stimulus).
Figure 6.8: Impedance in its complex representation for the first study case (left: first
measurement; right: second measurements) for pain situations only.
The impedance has been estimated by means of (6.9) and depicted by its com-
plex impedance. The confidence intervals for each study case are presented in
table 6.2.
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Figure 6.9: Impedance in its complex representation for the second (left) and third (right)
study cases for pain situations only.
Case study Mean Min Max Std
1 (first measurement) 0.4536 0.3291 1.5060 0.1309
1 (second measurement) 0.4512 0.3369 1.4432 0.1180
2 0.2050 0.1085 0.7003 0.0635
3 0.3421 0.2447 1.1924 0.1114
Table 6.2: Confidence interval for the investigated case studies. Std denotes the standard
deviation.
An analysis on the sum of absolute values of the frequency response com-
plex impedance in terms of boxplot representation for all volunteers has been per-
formed. It can be noticed that for each study case a different number of partici-
pants have been evaluated. This is due to the fact that one volunteer has failed the
repetition test. However, for the proof-of-concept of the method and device the
Figure 6.10: Case study 1: Boxplot analysis of the absolute values of the frequency
response complex impedance in all individuals. Left: first nociception stimuli; Right:
second nociception stimuli.
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performed analysis is sufficient. In Figure 6.10 the results for the first case study
(first and second pain stimuli) are presented.
Figure 6.11: Case study 1: Multiple comparison test among individual absolute values of
impedances during first nociception stimuli (left) and second nociception stimuli (right).
It can be noticed that eight subjects are in the same range of magnitude while
one subjects has a significantly lower impedance. This volunteer is a pregnant
women (in 6 months). One might consider that such a difference is normal since
the amount of liquid in the body is higher in pregnant womens that in not preg-
nant womens. During pregnancy changes of the circulatory system, respiratory,
metabolic, hormonal, etc. are occurring. All these changes may also contribute on
Figure 6.12: Case study 2: Boxplot analysis of the absolute values of the frequency
response complex impedance in all individuals. Left: first nociception stimuli; Right:
second nociception stimuli.
pain perception. In the case of the second stimuli (Figure 6.10-right) a difference in
impedance is observed in all patients. This indicated that each volunteer has a pain
memory effect (i.e. not fully recovered from the first pain stimulus applied). From
here one may conclude that: there is a trend of impedance when a mechanical stim-
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ulus is applied; the developed prototype can detect the changes in impedance and
meaningful measurements can be performed. Additional, multiple comparison of
means has been performed to see differences between the impedance absolute val-
ues of the two nociceptor stimulation interval during the first case study. Results
are given in Figure 6.11.
Figure 6.13: Case study 2: Multiple comparison test among individual absolute values of
impedances during first nociception stimuli (left) and second nociception stimuli (right).
Figure 6.14: Case study 3: Multiple comparison test among individual absolute values of
impedances during first nociception stimuli (left) and second nociception stimuli (right).
Same analysis has been performed for case study 2 and 3 and the results are
given in Figures 6.12-6.14. One may notice that the results obtained for the third
investigated case is significantly different from the others. Third case study con-
sists of performing the same measurement protocol as in first and second case but
on a different day. It is important to be mentioned that each participant has been
measured in the same period of the day as for previous case. This is important in
order to have consistency in the state of the participant. The difference observed
in the third case might indicate that the initial conditions have changed but this
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hypothesis needs further investigation.
Figure 6.15: Case study 3: Boxplot analysis of the absolute values of the frequency
response complex impedance in all individuals. Left: first nociception stimuli; Right:
second nociception stimuli.
To analyse the variability within individual among the three study cases, the
frequency response obtained using (6.9) has been used. For this analysis, the ab-
solute values of the frequency response complex impedance per excited frequency
point has been used. The results are given in Figures 6.16-6.17. From these fig-
ures it can be noticed that for most of the volunteers there is a difference within
individual per protocol.
Figure 6.16: Comparison between case study 1 and case study 2.
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Figure 6.17: Comparison between case study 2 and case study 3.
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6.4 Interlaced zero-pole impedance model
The transfer function provides a basis for determining important system response
characteristics without solving the complete differential equation. As defined, the
transfer function is a rational function in the complex variable s = σ+ jω, that is:
H(s) =
bms
m + bms
m−1 + · · ·+ b1s+ b0
ansn + an−1sn−1 + · · ·+ a1s+ a0 (6.10)
It is often convenient to factor the polynomials in the numerator and denominator,
and to write the transfer function in terms of those factors:
H(s) =
N(s)
D(s)
= K
(s− z1)(s− z2) . . . (s− zn−1)(s− zm)
(s− p1)(s− p2) . . . (s− pn−1)(s− pn) (6.11)
where the numerator and denominator polynomials, N(s) and D(s), have real co-
efficients defined by the system’s differential equation and K = bm/an. As writ-
ten in (6.11) the zi’s are the roots of the equation when N(s) = 0 and are defined
to be the system zeros. The pi’s are the roots of the equations whenD(s) = 0 and
are defined to be the system poles. All of the coefficients of polynomials N(S)
and D(s) are real, therefore the poles and zeros must be either purely real, or ap-
pear in complex conjugate pairs
In Figures 6.18-6.25 the measured impedance and the estimated impedance us-
ing the zero-pole interlacing method are shown. In these figures the results for one
volunteer for all three study cases are presented. From these results we may con-
clude that there is a good correlation between measured and estimated impedance.
This is due to the advantages represented by this method. More specifically,
given these zero-pole interlacing the model can capture the ”fluctuations” in the
measured impedance. However, this model has 13 parameters to be estimated, i.e.
a complex model. For the results presented in this thesis the lsqnonlin method
has been used to estimate the model parameters. Given its complexity further
research has been conducted and a lumped fractional order impedance model has
been derived. The model and the results obtained are presented in section 6.5.
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Figure 6.18: First pain stimuli: Impedance in its complex representation for first case
study (first measurement). ′∗′ denote measured impedance and ’o’ denote the estimated
impedance.
Figure 6.19: Second pain stimuli: Impedance in its complex representation for first case
study (first measurement). ′∗′ denote measured impedance and ’o’ denote the estimated
impedance.
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Figure 6.20: First pain stimuli: Impedance in its complex representation for first case
study (second measurement). ′∗′ denote measured impedance and ’o’ denote the estimated
impedance.
Figure 6.21: Second pain stimuli: Impedance in its complex representation for first case
study (second measurement). ′∗′ denote measured impedance and ’o’ denote the estimated
impedance.
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Figure 6.22: First pain stimuli: Impedance in its complex representation for second case
study. ′∗′ denote measured impedance and ’o’ denote the estimated impedance.
Figure 6.23: Second pain stimuli: Impedance in its complex representation for second case
study. ′∗′ denote measured impedance and ’o’ denote the estimated impedance.
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Figure 6.24: First pain stimuli: Impedance in its complex representation for third case
study. ′∗′ denote measured impedance and ’o’ denote the estimated impedance.
Figure 6.25: Second pain stimuli: Impedance in its complex representation for third case
study. ′∗′ denote measured impedance and ’o’ denote the estimated impedance.
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6.5 Lumped multiscale model
In general, drug regulatory loops are becoming popular in clinical practice, with
prevalence in computer controlled anesthesia. There is evidence to support that
closed loop control of drug dosing systems for anaesthesia perform better than
manual control [162]. These control systems rely on the availability of a patient
model [163, 164]. Within the anesthesia regulation paradigm, detecting and quan-
tifying pain with an objective measure by means of a mathematical model is still
a missing piece in the puzzle. As such, pain is a complex process, involving a
manifold of chemical, physical and electrical sub-processes all sequenced in a sys-
temic context. A manifold of papers report on initiatives to characterize pain lev-
els from combinations of other featured signals available to the medical special-
ist. Hypnotic and opioid side-effects mark changes in other bio-signals as heart
rate, respiratory rate, mean arterial pressure, gas in- and ex-piratory percentages,
body temperature, etc. Hence, methods from artificial intelligence and data min-
ing domains have proven to be useful tools, e.g. multivariate analysis [165], fuzzy
logic [166, 167], neural networks [168, 169] etc.
The physiological pathway of pain can be described to four main processes
[170]:
• transduction - when a stimulus is applied to the skin, the nociceptors located
there trigger action potentials by converting the physical energy from a nox-
ious thermal, mechanical or chemical stimulus into electrochemical energy,
• transmission - the signals are subsequently transmitted in the form of action
potentials (similar to pulse trains) via nerve fibres from the site of trans-
duction (periphery) to the dorsal root ganglion, which then activates the in-
terneuron,
• perception - the appreciation of signals arriving in specified areas in the
cerebral cortex as pain, and
• modulation - descending inhibitor and facilitator input from the brainstem
that influences (modulates) nociceptive transmission from the spinal cord.
A linear input-output based model was identified by performing thermal cold
stimuli into dental nerves and measuring resulted electrical activity correlated to
pain [171]. The model was a simple second order transfer function with damp-
ing factor and impulse response corresponding to measured electrical activity in
interdental nerves. This crude model was further improved to better approximate
the intra-patient variability and plasticity of pain sensation after repeated stim-
uli [172]. Further in vivo tests indicated that modulation is present in the electrical
activity when pain is perceived by the subject, suggesting thus that a frequency
6-22 PROPOSED MODELS AND THEIR VALIDATION
dependence is necessary. Nonlinear terms in sine and cosine functions have been
introduced in [173] to predict this nonlinear effect.
Somewhat later, a review of multi-scale processes involved in nociception and
pain sensation has been made, summarizing all steps from thermal stimuli [174].
Although the review makes an excellent overview, it concludes that the mech-
anistic processes are far from being well understood and that engineering tools
need to be further employed for delivering useful models for assessing pain in
man. A model for electrical activity aroused from thermal nociceptor detection
and transmission at neuronal level is then given. The model captures in part the
pain pathway and thus is limited in its use to the anesthesia regulation paradigm.
Later studies on thermal pain indicated the presence of adaptability and variability
in pain sensation as a result of noxious stimulus intensity degree and pattern of
stimulation [175]. In engineering terms, this is due to variability of disturbance
profiles (i.e. stimuli) and thus the excitatory input to the measured response varia-
tion provides a spatio-temporal change in the path pathway. Simple linear models
of classical system engineering theory can no longer capture such changes without
increasing the complexity of the problem formulation.
In this chapter we present a view from system engineering standpoint making
use of multi-scale models to obtain a lumped minimal parameter characterisation
of nociception and pain pathways. We employ tools from mathematics, physics
and chemistry to equivalent electrical circuit analogues beyond classical linear sys-
tem theory. Fractional calculus and diffusion in heterogeneous medium is a key
ingredient in this paper. The originality of the approach is in the integrative manner
in which all sequences of nociception and pain related pathways are modelled, to
maintain a minimal number of parameters to be later identified from experimental
data. The tools used in this model derivation are borrowed from mathematics, i.e.
fractional calculus, since they are a generalization of the classical linear system
theory known in systems engineering. To the author’s knowledge, a mathematical
model based on such systematic derivation does not yet exist in literature.
Gate Control Theory:
The gate control theory (GCT) is a successful way to explain important features
of the pain process [150]. This theory says that the small fibres (Aδ and C) that
carry the information about noxious stimuli, while the larger (L) fibres (Aβ) carry
information about less-intense mechanical stimuli. As the signal from the small
fibres is routed through substantia gelatinosa (SG) to the central transmission cells
(T-cell) and onwards, the double inhibition (indicated by the minus signs) strength-
ens the signal, resulting that the sensation of pain is more easily evoked. However,
the signal from A-fibres activates the inhibitory function of substantia gelatinosa,
which will reduce the firing to transmission cells and suppress the pain in the end.
This theory was modified later in that it included excitatory (indicated by the plus
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signs) and inhibitory links from substantia gelatinosa to central transmission cells,
as well as descending inhibitory control from some structures in the brainstem.
The neuromatrix theory proposed by Melzak in 1999 [176], integrates multiple
inputs to produce the output patterns that evokes pain. The body-self neuromatrix
comprises a widely distributed neural network that includes somatosensory, limbic
and thalamo-cortical components. A schematic representation of the gate control
theory is given in Figure 6.26.
Figure 6.26: Schematic representation of gate control theory for signal transmission.
During consciousness, using MRI, it is possible to identify those brain areas
directly related to pain [119, 150]. Such a stimulus reliably leads to activation of
multiple brain areas, termed as the pain matrix. Different areas represent different
aspects of pain. The primary and secondary somatosensory cortices are activated
to discriminate the location and intensity of a painful stimulus. The anterior cingu-
late cortex, frontal cortex and anterior insula regions may be related the cognitive
and emotional components. The problem is that these areas show significant mod-
ulation depending on the context of the stimulus, e.g. degree of attention, anxiety,
expectation, depression and analgesic drug treatment.
To conclude this introductory description, the modelling of the pain pathway
can be summarized as follows: i) stimulus effect; ii) transduction; iii) transmis-
sion; iv) modulation and v) perception. All these segments will be described in the
remainder of the document by means of multi-scale modelling approach.
Multi-Scale Modelling Approach:
From Stimulus to Nociception Receptor Model:
Consider a semi-infinite medium with two spatial components: a source (S)
component and a tissue (T) compartment. Assume the S compartment is dis-
tributed source of diffusing species without degradation and the T compartment
is characterized by first order degradation without production. Introduce the term
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cs as the accumulated concentration of the S compartment (i.e. as a result of the
stimulus) and cf the concentration in the T compartment. The overall solution is
the sum of the two terms
c(x) = cs(x) + cf (x) (6.12)
with the two domains assumed to be orthogonal, i.e. cs(x) = 0, in the distal
compartment x > L and cf (x) = 0 in the proximal compartment x < L, with
L the depth of the tissue layers. A continuous and smooth solution implies the
equilibrium conditions:
cs(x)|x=L− = cf (x)|x=L+ (6.13)
∂cs
∂x
(x)|x=L− = ∂cf
∂x
(x)|x=L+ (6.14)
and boundary conditions c(0) = 0; c(∞) = 0.
The amount of extracellular space (ECS) varies as a function of tissue structure,
function, and geometry within a system or an organ, i.e liver, arteries, heart, lungs,
brain, muscle, fat, etc. Impeded diffusion can be thus modelled either by using
classical diffusion laws, or by anomalous laws following fractional calculus tools.
Classical diffusion considers that the medium imposes only a spatial impedi-
ment on the diffusing species and does not change the diffusion law. For example,
in [177] the densely packed cells of the brain and their interstitial spaces resemble
a porous medium with two phases, i.e. an intra- and an extra- cellular phase. Dif-
fusion in the permeable phase of the porous media is analogous to the diffusion in
the narrow spaces between brain cells, i.e. the ECS. In our case, we consider the
permeable phase as that being with fast time constants, i.e. the fat cells and other
mediums without fast electrical conductivity are thus representing the ECS.
Volume transport of species having concentration c is governed by rescaled
reaction-diffusion equation:
∂c
∂
t =
D
λ2
∇2c+ s
α
− κc, with λ =
√
D
D
(6.15)
where the stimulus source term is denoted by s, the clearance term by k(c) = κc
is assumed to be first order decay and D is the diffusion coefficient (i.e. defined as
length2/time). Additionally, we have the dimensionless parameters of tortuosity
λ and porosity α, and the clearance rate κ (1/time). Tortuosity can be considered
as the linear correction for the anomalous diffusion in a complex medium [178].
Rename D = Dλ2 and s =
s
α and the transport equation can be redefined using
fractional calculus as
∂c
∂t
= D∇∇βc+ s− κc (6.16)
where ∇β denotes the fractional order Fick’s law, i.e. the fractional flux in the
medium. This form of diffusion naturally implies spatial non-locality and can be
derived rigorously using spatial averaging theorems [179, 180].
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Introducing the Caputo definition of an differ-integral as [5]:
Dβaf(x) =
1
Λ(1− β)
∫ x
a
f ′(t)
(x− t)β dt (6.17)
where Λ is the Euler gamma function and reducing the system of coordinates to the
axial variable it follows that diffusion is given by −DDβa c, as following from the
derivation presented in [181]. Introducing a mass conservation law for the particle
concentrations it follows that
∂c
∂t
= D
∂
∂x
Dβ0 c+ s+ κc (6.18)
whose explicit solutions have been given in [181].
Hence, we have that the model from stimulus to nociceptor receptor is gov-
erned by a diffusion equation in heterogeneous medium depending on time along
single linear spatial dimension. At this point we can describe the contact surface of
the stimulus as an ultracapacitor whose impedance can be formulated as a function
of the porous nature of medium [182].
The Impedance Model:
Signalling pathways is limited by ionic diffusion and electrical cellular stimu-
lation above a minimal threshold value. Geometry dependent diffusion impedances
have been derived in [16,17] for several particle geometries: planar, cylindrical and
spherical. In our case, the specific geometry is due to that localization of noxious
stimuli on different types of tissue structures, e.g. skin (planar), muscle (cylindri-
cal) or organ (spherical). Sufficiently low frequencies it appeared that impedances
behave as a resistor in series with a capacitor with specific terms according to ge-
ometrical features. The electrochemical impedance of the Na+/K+ pump for
signalling pathways of nociceptor stimulus involves activation of material parti-
cles and can be considered as a charge transfer process. At high frequencies (i.e.
above 1 Hz in most ultracapacitor cases) the overall impedance does not depend on
geometrical features and follows the frequency dependence of its complex values
as in a modified circuit:
Z(s) = R+
Rc
1 + τcs
+ Zm(s) (6.19)
where R is a threshold value (i.e. the gate control theory on-off signalising con-
dition), Rc and τc values related to the overall cellular impedance and Zm the
bounded diffusion impedance from molecular level dependent on anomalous dif-
fusion geometry. The charge transfer characteristic pulsation frequency is then
ωc =
1
τc
.
The fractional differ-integral operator can be expressed as a continuous integer
order system approximating the fractional term in a limited bandwidth, synthesized
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by cascading elementary phase-delay filters within the bandwidth [183]. This ap-
proximated filter is truncated at low and at high frequency boundaries. When con-
sidering the asymptotic behaviour of bounded diffusion impedance models at low
and high frequencies, it can be observed that they behave as a classical integrator
and an integrator of non-integer order n=1/2. The blocking diffusive behaviour is
thus modelled by a gain b0 and a fractional integrator I:
Zm(s) =
b0
s
+ b1I(ωb, s) (6.20)
The asymptotic behaviour at low frequencies (i.e. ω  wb) is
Zm|ωb = b0
s
+ b1ω
−n
b (6.21)
with n the fractional order which for homogeneously diffusion patterns is close to
the value of 0.5. It follows thus the overall fractional impedance model as
Z(s) = R+
Rc
1 + τcs
+
b0
s
+ b1I(ωb, s) (6.22)
The Signalling Pathway Model:
Typical dynamic processes observed in the neuron include diffusion phenom-
ena [184, 185], electrochemisty [186] and bistability [187]. Each of these features
has been shown previously to be captured by power law models or fractional order
derivatives [119]. A typical feature of the fractional order dynamics is a phase
constancy observed over a limited frequency range. Intuitively, one expects that
the lumped simplification of the complex dynamics governing the neuronal mech-
anisms would also exhibit a phase constancy. Our previous results confirm this
expectation and the ladder network model presented in [188] can be employed
with complex elements to capture specific neural structures (e.g. visual cortex,
hippocampus, corpus callosum, etc).
The further use of the cable theory and consequently the equivalent recurrent
ladder network for information transmission of nociceptor activity implies knowl-
edge of some time-space dependent features. The geometrical and morphologi-
cal features of the neural structure for propagating pathway determine the global
dynamic behaviour of the transmission network. By changing the neuron inter-
connectivity (i.e. selective connectivity), the properties and dynamics of the struc-
ture may vary, hence adapt for various purposes. In this way, adaptability and
variability in sensitivity can be captured.
The longitudinal and transversal impedances can be defined as a function of
voltage and current:
Zlm(s) =
Um−1(s)− Um(s)
Im−1(s)
(6.23)
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and
Ztm(s) =
Um(s)
Im−1(s)− Im(s) (6.24)
from which we can use: Um(s)− Um+1(s) = Zlm+1(s)Im(s), leading to:
Im(s)
Um(s)
=
1/Zlm+1(s)
1 + Um+1(s)Im(s)Zlm+1(s)
(6.25)
and respectively Im(s)− Im+1(s) = Um+1(s)Ztm+1(s) , leading to:
Um+1(s)
Im(s)
=
Ztm+1(s)
1 + Ztm+1(s)
Im+1(s)
Um+1(s)
(6.26)
From (6.25)-(6.26), the total admittance of the ladder at level m = 0 is given by:
Y1(s) =
1/Zl1(s)
1 +
Zt1(s)/Zl1(s)
1 + Zt1(s)
I1(s)
U1(s)
(6.27)
If we calculate the total admittance until m = 1, we have that:
Y2(s) =
1/Zl1(s)
1 +
Zt1(s)/Zl1(s)
1 +
Zt1(s)/Zl2(s)
1 +
U2(s)
I1(s)Zl2(s)
(6.28)
or, equivalently,
Y2(s) =
1/Zl1(s)
1 +
Zt1(s)/Zl1(s)
1 +
Zt1(s)/Zl2(s)
1 +
Zt2(s)/Zl2(s)
1 + Zt2(s)
I2(s)
U2(s)
(6.29)
From (6.27)-(6.29) one may generalize via recurrence the form of the total admit-
tance with m = N cells, for N →∞:
YN (s) =
1/Zl1(s)
1 +
Zt1(s)/Zl1(s)
1 +
Zt1(s)/Zl2(s)
1 +
Zt2(s)/Zl2(s)
. . .
. . .
1 +
ZtN−1(s)/ZlN (s)
1 + ZtN (s)/ZlN (s)
(6.30)
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which is, in fact, a continued fraction expansion. If in this network, we can ex-
press each compartment as a recurrent function of the first compartment, then the
total impedance of such a network exhibits a phase–constancy [189]. This phase
constancy can be positive or negative, depending on the values of Zt and Zl as a
function of the frequency. We shall make use of such generalized network model
to determine the neuron network impedance model.
Considering any combination of cellular composition it follows the general
form of this continuous fraction expansion:
YN (s) =
W ′(s)
1 +
W (s)
1 +
W (s)/α
1 +
W (s)/αη
1 +
W (s)/α2η
. . .
. . .
1 +
W (s)/αN−1ηN−2
1 +W (s)/αN−1ηN−1
(6.31)
which is a generally valid form, irrespective of the definitions ofW (s) andW ′(s).
For any |W (s)| > 1, this general form (6.31) can be approximated by a lumped
admittance whose form depend on the functions W (s) and W ′(s) in which exists
at least one term in fractional-order given by:
γ =
log(α)
log(α) + log(η)
(6.32)
The frequency interval where the convergence to this form is valid, hence the
constant-phase behavior in the frequency response of such a ladder network, is
given by the condition imposed via |W (s)| > 1.
In [190], an early study on fractional dynamics for distributed relaxation pro-
cesses in sensory adaptation, the authors found that the fractional derivative and
its Fourier transform sα = jωα were able to capture the wide dynamic range of
sensory adaptations. Distributed relaxation processes are common in cells and tis-
sues, involving electrochemical reactions. The latter have been shown to be well
characterized by the fractional order circuit element Z = Z0ω−α × e(jatg(piα2 ))
which exhibits constant phase dynamics [119]. The link from the frequency do-
main to time domain of such a fractional order element can be derived by means
of the fractional derivative definition. Suppose the impedance written in Laplace
domain:
z(s) =
v(s)
i(s)
= R+
1
sαC(s)
(6.33)
then the transient voltage response to a step in the applied current is described in
time domain by
V (t) = I0R+
I0t
α
CΓ(α+ 1)
(6.34)
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which gives a power law response. This shows that there must exist a link between
the fractal dimension observed in the time domain EEG signals and the frequency
response fractional order dynamics. The current knowledge on structural arrange-
ments of neural networks and their dynamics is not yet mature to fully account the
complex dynamics observed in the EEG.
Fractional order dynamic models of complex, multiscale systems such as the
brain, account for anomalous behavior through a simple extension of the order of
the algebraic operations from integer to fractional. In the time domain, this exten-
sion is manifested through incorporation of a variable degree of system memory
through convolution with a power law kernel exhibiting fading memory of the
past [119]. In system engineering terminology this is also known as a forgetting
factor, a weight on the past data between 0-1, whereas fractions closer to 0 indicate
the past is not important.
Pain Perception Model:
The perception model based on exponential and power law combined functions
seems to be a good candidate for capturing essential electrical activity modulated
in brain [191]. Plasticity in synaptic variance is introduced in a layer-based sen-
sory area in cortex by reverse node engineering modelling. In the case of pain
perception, the combined effect can be obtained by using the Mittag-Leffler func-
tion, which is well-known to capture hybrid exponential and power-law behaviour
in biological tissues [119].
Diffusion of perception sensory activity in brain using Mittag Leffler function
in time domain corresponds to a non-integer order derivative easily expressed in
frequency domain [22]. Layered activity can be represented by ladder networks
with serial connection of RC-cells. To account for plasticity, the RC cells are
not identical, instead they behave as a memristor with unbalanced dynamics. For
instance, first pain perception is more intense than the second, given the latency
of the delayed pain stimulus (i.e. sharp first increase followed by slowly decaying
tail).
Assuming the brain-cortex area as a porous tissue whose porosity varies (i.e
intra- and extra- cellular space tissue with different densities), one can model
the changes in viscosity as a function of this porous density. It has been shown
that fractional order derivatives are natural solutions to anomalous diffusion equa-
tions [12, 15]. Time variations of information flow profiles in time-dependent
viscous fluids have been also characterized with the same Mittag-Leffler func-
tion [192]. The use and physical interpretation of this very useful fractional cal-
culus tool has been discussed in several works, e.g. [7, 193–195]. The advantage
of using the Mittag-Lefler function is that it allows introducing memory formal-
ism [196], therefore taking into account the tissue rheology. The mixed area in
brain tissue will introduce a dynamic viscosity and thus a dynamic perception of
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nociceptor induced pain.
To characterize this dynamic formalism, we make use of the Mittag Leffler
function. Let the Riemann-Liouville fractional integral defined in [197] be given
by:
Jβt f(t) =
1
Γ(β)
∫ t
0
(t− τ)β−1f(τ)dτ (6.35)
for positive values of β and time t over integration step dτ . Assuming uni-directional
information flow and piecewise constant density, we have that stress and strain re-
lation in local tissue areas is generalized to:
τij = 2µ0J
α
t eij (6.36)
with τij the stress tensor, µ is the dynamic viscosity, eij is the strain tensor, 0 <
α < 1 and positive time t. The Laplace transform of the fractional integral is given
by:
L(Jαt u(y, t))(s) = s
−αu˜(y, s) (6.37)
We also have that: ∫ ∞
0
e−sttµ−1Eν,µ(atν)dt =
sν−µ
sν − a (6.38)
where we make use of the Mittag-Leffler function:
Eν,µ =
∞∑
r=0
sr
Γ(νr + µ)
(6.39)
Solutions for bounded domains fractional diffusion equations can be found using
the Mittag-Lefler function. We have the following initial/boundary value problem:{ ∂tu = µ0∂yyJαt u, for α ∈ (0, 1)
u(0, t) = u(2r, t) = 0, for t ≤ 0
u(y, 0) = U0 = ct, for 0 ≤ y ≤ h
In this problem assume a constant initial velocity field u(y, 0) = U0 in a
determined plane, with null boundary conditions. Using the exact solution in a
boundary domain given in [192], information signal velocity profiles are given as
a function of (6.39):
u(y, t) = U0
2
pi
∑∞
n=1Eα+1
(−√µ0a2n2tα+1) sin(ayn)n (1− cos(npi))
(6.40)
with 1 < (α+ 1) < 2, n the wave number, and a = pi/2r with 2r the diameter of
a sphere denoting the stimulated area.
The result of memory effects due to time variability of the viscosity coefficient
is an anomalous fractional Mittag-Leffler oscillation function. This indicates that
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fractional order impedance models may be a good instrument to describe global
and local damping due to local time variability of the viscosity coefficient, linked
to levels of consciousness [198].
The multi-scale lumped model:
Given the processes characterized hitherto, we can now proceed to approx-
imate them with lumped terms. The stimulus effect to nociception reception is
enabled essentially by diffusion characterised by an ultracapacitor. The gate con-
trol theory acts at lower frequencies as a resistance and at high frequencies as
a ultracapacitor. The signalling pathway model is reduced to a fractional order
integro-derivative function (depending on the sign of the fractional order) - this
term essentially captures whether or not the information is taken up to the brain.
The pain perception model is also an integro-derivative function capturing levels
of perception of noxious stimuli in the brain.
It follows that the complete mathematical model expressed as an impedance in
Laplace variable s is given by
Ztot(s) = R+
D
sα1
+
S
sα2
+ Psα3 (6.41)
where 0 < α1,2,3 < 1 andR,D, S, P are real numbers. Not all terms in this model
are necessary at all times, as some of the physiological processes may be impaired
in some applications (e.g. analgesia will put zero the effect of the perception term
in P ). The units are arbitrary, as the model is defined as a difference to the initial
state of the patient - due to the use of fractional derivatives - and not as absolute
values. This enables patient specificity since no generic model is assumed to be
valid and thus broadcasts a new light upon the interpretation of such models.
Model Validation:
Apart from the non-parametric identification performed with (6.9) and the
zero-pole interlacing method, a parametric identification has been performed using
the fractional order model from (6.41). The results obtained using the fractional
order model impedance (6.41) are presented in Figures 6.27-6.34. In this part of
the thesis only the results for one volunteer for all study cases are presented. The
results for the other participants are included in Appendix C.
From the results presented in this section a good correlation between the mea-
sured impedance and the estimated impedance using (6.41) can be observed. One
may argument that the fitting with the zero-pole interlacing method gave better re-
sults (for more subjects) than the lumped fractional order impedance model. This
might be indeed the case, but it has to be taken into account that the zero-pole in-
terlacing model has 13 parameters to be estimated while for the lumped fractional
model we have only 7.
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Figure 6.27: First pain stimuli: Impedance in its complex representation for first case
study (first measurement). ′∗′ denote measured impedance and ’o’ denote the estimated
impedance.
Figure 6.28: Second pain stimuli: Impedance in its complex representation for first case
study (first measurement). ′∗′ denote measured impedance and ’o’ denote the estimated
impedance.
The next challenge is to identify the physiological meaning of each of these
parameters. For this, further research, beyond this thesis, will be performed. A
clinical study, for which the ethical committee EC/2017/1517 has been already
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Figure 6.29: First pain stimuli: Impedance in its complex representation for first case
study (second measurement). ′∗′ denote measured impedance and ’o’ denote the estimated
impedance.
Figure 6.30: Second pain stimuli: Impedance in its complex representation for first case
study (second measurement). ′∗′ denote measured impedance and ’o’ denoted the
estimated impedance.
submitted, will be conducted at Ghent University Hospital. This study will take
place in the first half of 2019. In parallel the necessary steps to apply for an
observational study at the hospital in Brescia (via prof. Antonio Visioli, Brescia
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University) have been taken. During these observational studies patients in the
post-operative care unit will be monitored with the ANSPEC-PRO device.
Figure 6.31: First pain stimuli: Impedance in its complex representation for second case
study. ′∗′ denote measured impedance and ’o’ denote the estimated impedance.
Figure 6.32: Second pain stimuli: Impedance in its complex representation for second case
study. ′∗′ denote measured impedance and ’o’ denote the estimated impedance.
During the clinical trials impedance will be recorded but also additional in-
formation such as: NRS score (given by the patients), heart rate, cardiac output,
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Figure 6.33: First pain stimuli: Impedance in its complex representation for third case
study. ′∗′ denote measured impedance and ’o’ denote the estimated impedance.
Figure 6.34: Second pain stimuli: Impedance in its complex representation for third case
study. ′∗′ denote measured impedance and ’o’ denote the estimated impedance.
etc. will be registered. From the data available after this observational study, a
rigorous analysis will be performed. Given the additional information available
and the patient biometric parameters a correlation between model parameters and
their physiological meaning will be derived. The identification values of the model
parameters are presented in table 6.3. Although the identification results are satis-
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factory and we have noticed that there are differences in model parameters between
the investigated case studies a more in depth analysis is needed. Therefore, further
research with respect to the fractional order model parameters will be conducted.
Also, an analysis between fractional order model parameter and the biometric pa-
rameters has been conducted in order to identify if there is any correlation between
them. From this analysis no clear conclusion could be taken. We have noticed that
for some of the fractional order parameter there is a correlation for others not.
Therefore, these results have not been included in this chapter of the thesis but in
Appendix A. Further research with respect to this particular item will be performed
after this thesis when also a higher number of subjects will be investigated such
that statistically significant conclusions can be taken.
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6.6 Summary
In this Chapter the proposed model and their validation are presented. Four models
have been investigated: Cole-Cole model, non-parametric impedance model, zero-
pole interlacing model and lumped fractional order impedance model. All these
models have been validated on real data and the outcome of this chapter is that
the fractional order impedance model can capture the changes in impedance when
a pain stimulus is applied. Although the obtained results are satisfactory further
research is needed and the following tasks need to be performed:
• measurements on larger number of participants to enable statistical mean-
ingful conclusions;
• a clinical study where patients are standardly treated for pain (i.e. not a
controllable environment, pain is already present);
• perform a rigorous analysis of these measurements to extract the required in-
formation for a physisological interpretation of each parameter in the model;
• an index needs to be derived to indicate the level of pain;
All these tasks are beyond the scope of this thesis.
7
Conclusions
In this Chapter the conclusions of the work presented in this thesis are addressed.
The main contributions and further work are emphasized. The conclusions are
drawn from two perspectives: diffusion model of gas exchange in the lungs and a
model to characterize the nociceptor pathways.
Diffusion of gas in the lungs is a passive physical process that exchanges oxy-
gen and carbon dioxide between the alveoli and the blood (in the lungs) and be-
tween the blood an the cells (in the periphery). Based on the theory presented in
Chapter 2 and the results given in Chapter 3 we have shown that the complex phe-
nomenon of gas exchange in the lungs can be approximated with a fractional order
model. In this thesis, the importance of diffusion in patients with COPD disease
has been investigated. Measurement of the diffusion factor might be of importance
in (early) detection of COPD disease. The single breath method became the most
generally accepted method. In this thesis emerging tools from fractional calculus
have been used to capture changes in COPD disease and to understand their effect
on the model parameters.
The results presented in this thesis indicate a direct link relation between the
T index and the heterogeneity in COPD lungs. Although the results obtained are
promising there are still challenges to be solved. The model presented in this
thesis is an approximation based on analogy, hence the theoretical link between
diffusion in the lungs and the model presented in Chapter 2 will be further inves-
tigated. Moreover, in this thesis a relatively small study in a somewhat heteroge-
neous group of COPD patients has been performed.
7-2 CONCLUSION
According to the literature, detection and parameterization of nociceptor activ-
ity is of crucial importance for treatment in chronic pain patients, in post-surgery
patients, rehabilitation and follow up studies of new medication development. The
lack of system engineering tools to capture the most important multi-scale pro-
cesses involved in the reception, transmission and perception of pain has kept on
a slow pace the potential development of pain management services. A specific
domain of application where such models are greatly needed is the depth of anes-
thesia regulatory paradigm. As such, the model presented in this thesis enables
new horizons and has the potential to unlock the current state of art in this specific
area of application.
Patient specificity implies the ability to characterise changes in the various
process dynamics involved in nociceptor pathways and perception. The proposed
parametric model is unique in its formalism and systems engineering approach.
The lumped model provides the most versatile features to capture changes in dy-
namic responses, with the minimal number of parameter values. This keeps the
numerical complexity to a low level, enabling deployment on real-time platforms
and fast computation rates for identification from real-life data.
The proposed model considers a time-frequency mathematical formulation. It
has been shown that many biomedical signals may benefit from time-frequency
analysis. Since the frequency content of many biomedical signals can fast with
time (i.e. changes in impedance when a pain stimulus is applied are very fast),
the time-frequency analysis allows us to capture these changes. This is of great
importance in pathology cases, where changes in tissue structure and morphology
affects directly the dynamic profiles of drug diffusion, permeability and molecular
binding. Specific structural changes with disease may also reveal various paths
of deep tissue trapping of drug and latency nodes which could explain effects ob-
served in long-tailed observations. This work enables a mapping of the various
components of the pain pathways. The description follows the micro- and macro-
structural elements. The end result is an innovative and original methodology to
capture the signalling pathways and deliver an objective, independent and useful
measure for pain.
In this thesis, the first steps towards a sensor to measure the pain level in an
objective manner and a model of nociception pathway have been made. The result
is the ANSPEC-PRO monitor, non-invasively measuring pain by means of skin
impedance. The prototype has been validated at this moment only in awake volun-
teers with self-induced nociceptor excitation (i.e. mechanical pain stimuli). Given
the low subjects number and the controlled environment in which the device has
been tested, an ethical committee application (EC/2017/1517) has been submit-
ted for measurements at the University Hospital Ghent. In parallel, the necessary
steps for submitting an ethical committee application at Brescia University Hospi-
tal have been taken. The aim of these observational studies is to observe patients
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in the post-operative care unit. These patients are treated for pain following the
standard procedure (i.e. based on NRS scale).
7.1 Future perspectives
Anesthesia paradigm consists of three main components: hypnosis, neuromuscular
blockade and analgesia. The first two components are well now mature for integra-
tion in a single environment. Hence, the missing piece is analgesia. The results of
this thesis will enable the next steps towards a complete regulatory dynamic system
for controlling general anesthesia by means of its all three components. However,
the proposed model cannot be yet used in closed loop and a further development
is required. More specifically, a correlation with drug concentration needs to be
made. This aspect has not been addressed in this thesis. A possibility to measure
drug concentration is using blood sample. However, to include this information
in closed loop continuous measurement of drug concentration is necessary. Given
the technological advances nowadays a non-invasive or minimally invasive mea-
surement of drug concentration would be ideal. This is not yet available and a
first hypothesis to be investigated is similar to continuous measurement of glu-
cose concentration. More specifically, a thing wire sensor is inserted under the
skin and measures the glucose concentration in the interstitial fluid. Studies have
shown that there is no significant time lag among the interstitial fluid, capillary
and venous glucose levels. At this moment the model can be used as disturbance.
For instance if we know the surgery profile we can used the developed model as a
disturbance to predict that an increase in the nociception level will occur.
The aim beyond this doctoral thesis is to develop a bullet-proof analysis of a
complete regulatory dynamic system for controlling general anesthesia by means
of all its three components: hypnosis, analgesia and neuromuscular blockade. To
date, nowhere worldwide exist such a complete system in simulation studies, let
alone in practice. This system will feature multiple input and multiple output
variable analysis, model development and adaptation and robust, stable, adaptive
control algorithms. Safety loops will be mimicked into the system, as well as sur-
gical disturbances and noxious stimulation profiles. All these independent features
are available in their single regulatory loop. Their combination and the effect of
their combination on the patient state profiles is yet unknown.
The longer term objective will be to implement a clinical onset for this com-
plete regulatory system following EC advise and policies at Ghent University Hos-
pital. This is a challenging and unconventional research which requires the collab-
oration and acceptance from the medical practitioners. Given our long-standing
collaboration with Ghent University Hospital and other hospitals in Europe (i.e.
Breascia University) ethical committee files will be submitted to validate the de-
veloped automated anesthesia system.

A
ANSPEC-PRO Device
In this Appendix the development of a measurement device for continuous mon-
itoring of changes in skin impedance as a function of an applied stimulus is pre-
sented. This proof of concept device has been developed starting from the per-
spective that a pain stimulus can be detected from a change in skin impedance as a
function of time and frequency. The skin is a black box and in order to obtain the
impedance the skin is excited with a known voltage and simultaneous measuring
the current flowing through the skin. The relation between this input voltage V (s)
and output current I(s) is:
Z(s) =
V (s)
I(s)
(A.1)
Notice that skin impedance Z(s), input voltage V (s) and output current I(s) are in
function of s = jω and, thus, are dependent on frequency (ω = 2pif ) of the exci-
tation signal [201]. To obtain a wide range of information on the behaviour of the
skin impedance the skin is excited at different frequencies. For this identification
method with multiple exciting frequencies a multisine signal is used [202]. This
signal is a superposition of a number of sines with different frequencies. Using
Non-Parametric Identification techniques the impedance Z(s) can be estimated.
As mentioned before, this transfer function Z(s) will change in time, due to pain
stimuli or other external influences [203]. This will increase the complexity of the
Non-Parametric Identification as a time factor will be introduced.
The device will consist of the following subsystems that will work together:
hardware, software and data analysis. Measuring current is not easy compared to
voltages and therefore the signal is conditioned and the current is transformed to
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a voltage which can be interpreted by the measuring device (see Figure A.1). A
signal is designed off-line (a priori). This signal v(t) is sampled and needs to be
sent to an analogue output port, using zero-order hold, with a certain sampling
frequency, fs. Simultaneously, the current i(t) coming from the skin needs to be
measured. The voltage v(t) and current i(t) are saved in a file that is defined by
the user.
Figure A.1: Block diagram with the skin impedance Z(s, k) as black box system; The
bioimpedance is in function of the frequency and discretised time k.
General description of the investigational device and its components including
materials used: The developed device is non-invasive, as electrodes are temporar-
ily attached to the skin of the human body. The electrodes and electrode con-
nectors are CE-marked (according to MDD93/42/EEC). The National Instruments
CompactRIO that is used to measure the patient fulfills the following electrical
equipment safety standards:
• IEC 61010-1, EN 61010-1
• UL 61010-1, CSA 61010-1
• EN 60079-0:2012, EN 60079-15:2010
• IEC 60079-0: Ed 6, IEC 60079-15, Ed 4
• UL 60079-0; Ed 5, UL 60079-15; Ed 3
• CSA 60079-0:2011, CSA 60079-15:2012
Regarding the electromagnetic compatibility the cRIO meets the requirements of
the following EMC standards for electrical equipment:
• EN 61326 (IEC 61326): Class A emissions; Industrial immunity
• EN 55011 (CISPR 11): Group 1, Class A emissions
• AS/NZS CISPR 11: Group 1, Class A emissions
• FCC 47 CFR Part 15B: Class A emissions
• ICES-001: Class A emissions
The devices meets the essential requirements of applicable European Directives,
and therefore receiving the CE Mark, as follows:
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• 2014/35/EU; Low-Voltage Directive (safety)
• 2014/30/EU; Electromagnetic Compatibility Directive (EMC)
• 94/9/EC; Potentially Explosive Atmospheres (ATEX)
The device is built while taking into account the A.R.E.I. (Algemeen Regle-
ment op de elektrische installaties) regulations, that provides rules of thumbs for
safety of electrical equipment, regarding electrical shocks, safety, grounding, etc.
The device consists of two hardware parts: a laptop and a data-acquisition cir-
cuit. The two parts are interconnected through Ethernet cables that links the two
devices to a common network. The laptop is a standard laptop with the operat-
ing system Windows 7 Enterprise 64-bit and a INTEL(R) Core(TM) i7-6600U
CPU@2.80GHz processor.
Data-acquisition circuit consists of two DC-converters with galvanic separa-
tors, step-down transformers, that will output 24 V DC and +/-15 V DC. The +/-15
V DC will supply the power to the electrodes. The power is 3.75 VA and the trans-
former is approved according to the ENEC 10 (VDE) legislations. The safety class
of the transformer is class II, which indicates that it has a double insulation. The
voltage is rectified and a voltage regulator provides a short-circuit protection in its
package. A National Instruments (Texas, USA) device (cRIO9074 with NI9201-
and NI9263-slots) is used to excite a part of the skin with an off-line designed volt-
age signal. This voltage will induce a current in the circuit related to the impedance
of the human body. This current is captured and saved onto the laptop. A voltage
buffer limits the supplied current to +/-20 mA.
The user interface has been developed in LabView and the main block dia-
grams behind figure A.2 are presented below. In this interface, the following num-
bers are depicted:
1. Load the input signal;
2. Set the sampling frequency in Hz;
3. Set the frequency resolution in Hz;
4. Set the amplitude of output signal. This is to control saturation of the input
signal to the patient (see 10);
5. The number of seconds that are saved per data file.
6. After fields 1 to 5 and 7 are filled in, start acquiring by pressing 6 - Start
acquisition;
7. Create the paths and file name where to save the data. Remark that the data
is only saved when 9 - Save is selected;
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Figure A.2: The user interface on the laptop that controls the ANSPEC-PRO device
8. After acquiring press 8 - Stop to stop the acquisition;
9. The save-button should be highlighted to save data to the location indicated
in 7;
In figure A.3 the block diagram for software initialization and parameters defi-
nition is shown, followed by the acquisition block diagram presented in figure A.4.
The block diagrams for receiving and writing the data are presented in figures A.5
and A.6.
Table A.1 provides a list with all components used in the circuitry. The PCB
(printed circuit board) is made of Laminates (resin material), copper-clad lami-
nates, resin impreginated B-stage cloth (Pre-preg), and copper foil.
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Figure A.4: Acquisition block diagram in LabView.
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Figure A.6: Write block diagram in LabView.
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Module Name Company
cRIO cRIO-9074 National Instruments
cRIO NI-9201 National Instruments
cRIO NI-9263 National Instruments
cRIO PS-125 National Instruments
cRIO Ethernet cable (5E - patched) /
S PCB EELAB
S 2way PCB Terminal Block Phoenix
S Transformer 15V -3.5VA Block
S Diodes - 400V ON Semiconductor
S Electrolytic Capacitor (3300nF-35V) United Chemi-Con
S Voltage Regulator (+12V/1A) (MC7812) ON Semiconductor
S Voltage Regulator (-12V/1A) (MC7912) ON Semiconductor
S Heat Sink TO-220 AAVID-Thermalloy
S/VB 3way PCB Terminal Block Phoenix
VB Op Amp MC1458P Texas Instruments
VB 4way PCB Terminal Block Phoenix
VB Audio Connector (3 contacts, Jack 3.5) Pro Signal
VB Sensor Cable (3 electrodes, Jack 3.5) /
VB Foam, Hydrogel Electrode H92SG Kendall Covidien
VB Diaphoretic foam Monitoring Electrode 2230 3M
VB/TIA PCB Own Design
TIA Op Amp ADA4077-2 Analog Devices
TIA Resistance (1000Ω -5%) Velleman
TIA Ceramic Capacitor (10pF-50V) Kemet
Table A.1: Electrical Components; (cRIO) National Instruments’ compactRIO; (S) Op
amp voltage source; (VB) Voltage Buffer; (TIA) Transimpedance Amplifier;

B
Measurement results
Results obtained using the non-parametric impedance model
In Figures B.1 - B.6 the measurement results obtained for the first case study
are reported followed by the results for the second case study in Figures B.7 - B.9
and third case study in Figures B.10 - B.12. Next, the results only showing the
pain intervals are presented in Figures B.13 - B.18 for the first case study followed
by the results for the second case study in Figures B.19 - B.21 and for the third
case study in Figures B.22 - B.24.
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Case study 1 / All intervals (P-Pain/NP-No Pain)
Figure B.1: Volunteer 2: Impedance in its complex representation for the first study case
(left: first measurement; right: second measurements).
Figure B.2: Volunteer 3: Impedance in its complex representation for the first study case
(left: first measurement; right: second measurements).
Figure B.3: Volunteer 4: Impedance in its complex representation for the first study case
(left: first measurement; right: second measurements).
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Figure B.4: Volunteer 5: Impedance in its complex representation for the first study case
(left: first measurement; right: second measurements).
Figure B.5: Volunteer 6: Impedance in its complex representation for the first study case
(left: first measurement; right: second measurements).
Figure B.6: Volunteer 7: Impedance in its complex representation for the first study case
(left: first measurement; right: second measurements).
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Case study 2 / All intervals (P-Pain/NP-No Pain)
Figure B.7: Impedance in its complex representation for the second study case (left:
volunteer 2; right: volunteer 3).
Figure B.8: Impedance in its complex representation for the second study case (left:
volunteer 4; right: volunteer 5).
Figure B.9: Impedance in its complex representation for the second study case (left:
volunteer 6; right: volunteer 7).
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Case study 3 / All intervals (P-Pain/NP-No Pain)
Figure B.10: Impedance in its complex representation for the third study case (left:
volunteer 2; right: volunteer 3).
Figure B.11: Impedance in its complex representation for the third study case (left:
volunteer 4; right: volunteer 5).
Figure B.12: Impedance in its complex representation for the third study case (left:
volunteer 6; right: volunteer 7).
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Case study 1 / Only pain intervals
Figure B.13: Volunteer 2: Impedance in its complex representation for the first study case
(left: first measurement; right: second measurements).
Figure B.14: Volunteer 3: Impedance in its complex representation for the first study case
(left: first measurement; right: second measurements).
Figure B.15: Volunteer 4: Impedance in its complex representation for the first study case
(left: first measurement; right: second measurements).
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Figure B.16: Volunteer 5: Impedance in its complex representation for the first study case
(left: first measurement; right: second measurements).
Figure B.17: Volunteer 6: Impedance in its complex representation for the first study case
(left: first measurement; right: second measurements).
Figure B.18: Volunteer 7: Impedance in its complex representation for the first study case
(left: first measurement; right: second measurements).
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Case study 2 / Only pain intervals
Figure B.19: Impedance in its complex representation for the second study case (left:
volunteer 2; right: volunteer 3).
Figure B.20: Impedance in its complex representation for the second study case (left:
volunteer 4; right: volunteer 5).
Figure B.21: Impedance in its complex representation for the second study case (left:
volunteer 6; right: volunteer 7).
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Case study 3 / Only pain intervals
Figure B.22: Impedance in its complex representation for the third study case (left:
volunteer 2; right: volunteer 3).
Figure B.23: Impedance in its complex representation for the third study case (left:
volunteer 4; right: volunteer 5).
Figure B.24: Impedance in its complex representation for the third study case (left:
volunteer 6; right: volunteer 7).

C
Identification results
In this appendix the results obtained for the zero pole model and the fractional or-
der impedance model are presented. Both models have been validated on real data
and the outcome of this chapter is that the fractional order impedance model can
capture the changes in impedance when a pain stimulus is applied. An iterative
identification procedure has been performed in order to fit the model to the mea-
sured data. Iteration has been performed to avoid local minimum and the number
of iterations between the identified results varied between 2 and 4 in all data. The
iteration stopped when the model parameters have changed less than 5%. As for
the case of the non-iterative method, the using the iterative method the fitting of the
model to the real data did not worked for all cases. From the analysis performed
in this thesis we could not conclude is there is a correlation between the biomet-
ric data of the volunteers and model parameters. This can be due to the limited
number of volunteers but also given the homogeneity of the group. This will be
further investigated based on the data recorded during the clinical trial that will
take place at the UZ Gent. In this case the variety of patient type (e.g. body mass
index) will be more significant than in our group of volunteers and an analysis on
the variability among patients can be performed.
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FO model: Case study 1/First measurement/First pain stimuli
Figure C.1: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.2: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.3: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Case study 1/First measurement/Second pain stimuli
Figure C.4: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.5: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.6: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Case study 1/Second measurement/First pain stimuli
Figure C.7: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.8: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.9: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Case study 1/Second measurement/Second pain stimuli
Figure C.10: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.11: tLeft: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.12: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Case study 2/First pain stimuli
Figure C.13: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.14: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.15: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Case study 2/Second pain stimuli
Figure C.16: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.17: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.18: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Case study 3/First pain stimuli
Figure C.19: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.20: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.21: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Case study 3/Second pain stimuli
Figure C.22: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.23: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.24: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Model parameter analysis as a function of biometric data for each study case.
Case study 1/First measurement
Figure C.25: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.26: Left: First pain stimulus; Right: Second Pain stimulus
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Figure C.27: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.28: Left: First pain stimulus; Right: Second Pain stimulus
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Figure C.29: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.30: Left: First pain stimulus; Right: Second Pain stimulus
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Figure C.31: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.32: Left: First pain stimulus; Right: Second Pain stimulus
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Case study 1/Second measurement
Figure C.33: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.34: Left: First pain stimulus; Right: Second Pain stimulus
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Figure C.35: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.36: Left: First pain stimulus; Right: Second Pain stimulus
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Figure C.37: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.38: Left: First pain stimulus; Right: Second Pain stimulus
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Figure C.39: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.40: Left: First pain stimulus; Right: Second Pain stimulus
C-18 IDENTIFICATION RESULTS
Case study 2
Figure C.41: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.42: Left: First pain stimulus; Right: Second Pain stimulus
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Figure C.43: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.44: Left: First pain stimulus; Right: Second Pain stimulus
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Figure C.45: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.46: Left: First pain stimulus; Right: Second Pain stimulus
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Figure C.47: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.48: Left: First pain stimulus; Right: Second Pain stimulus
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Case study 3
Figure C.49: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.50: Left: First pain stimulus; Right: Second Pain stimulus
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Figure C.51: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.52: Left: First pain stimulus; Right: Second Pain stimulus
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Figure C.53: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.54: Left: First pain stimulus; Right: Second Pain stimulus
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Figure C.55: Left: First pain stimulus; Right: Second Pain stimulus
Figure C.56: Left: First pain stimulus; Right: Second Pain stimulus
C-26 IDENTIFICATION RESULTS
Zero-pole interlacing model Case study 1/1st measurement/1st pain stimuli
Figure C.57: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.58: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.59: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Case study 1/First measurement/Second pain stimuli
Figure C.60: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.61: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.62: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Case study 1/Second measurement/First pain stimuli
Figure C.63: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.64: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.65: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
APPENDIX C C-29
Case study 1/Second measurement/Second pain stimuli
Figure C.66: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.67: tLeft: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.68: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Case study 2/First pain stimuli
Figure C.69: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.70: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.71: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Case study 2/Second pain stimuli
Figure C.72: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.73: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.74: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Case study 3/First pain stimuli
Figure C.75: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.76: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.77: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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Case study 3/Second pain stimuli
Figure C.78: Left: Volunteer 2; Right: Volunteer 3. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.79: Left: Volunteer 4; Right: Volunteer 5. Blue denotes the identified model and
Red denotes the measured impedance.
Figure C.80: Left: Volunteer 6; Right: Volunteer 7. Blue denotes the identified model and
Red denotes the measured impedance.
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